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A
Mitochondrial diseases involving dysfunction of the respiratory chain are the
most common inborn errors of metabolism. Mitochondria are found in all cell
types besides red blood cells; consequently, patients can present with any symp-
tom in any organ at any age. ese diseases are genetically heterogeneous, and
exhibit maternal, autosomal dominant, autosomal recessive and X-linked modes
of inheritance. Historically, clinical genetic evaluation of mitochondrial disease
has been limited to sequencing of themitochondrial DNA (mtDNA) or several can-
didate genes. As human genome sequencing transformed from a research grade
eﬀort costing , to a clinical test orderable by doctors for under ,,
it has become practical for researchers to sequence individual patients. is the-
sis describes our experiences in applying “MitoExome” sequencing of the mtDNA
and exons of >  nuclear genes encoding mitochondrial proteins in ~ pa-
tients with suspected mitochondrial disease. In  infants, we found that 
harbored pathogenic mtDNA variants or compound heterozygous mutations in
candidate genes. e pathogenicity of two nuclear genes not previously linked to
disease, NDUFB and AGK, was supported by complementation studies and evi-
dence frommultiple patients, respectively. In an additional twounrelated children
presenting with Leigh syndrome and combined OXPHOS deﬁciency, we identiﬁed
compound heterozygous mutations inMTFMT. Patient ﬁbroblasts exhibit severe
defects in mitochondrial translation that can be rescued by exogenous expres-
sion ofMTFMT. Furthermore, patient ﬁbroblasts have dramatically reduced fMet-
tRNAMet levels and an abnormal formylation proﬁle ofmitochondrially translated
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COX. ese results demonstrate that MTFMT is critical for human mitochon-
drial translation. Lastly, to facilitate evaluation of copy number variants (CNVs),
we developed a web-interface that integrates CNV calling with genetic and pheno-
typic information. Additional diagnoses are suggested and in a male with ataxia,
neuropathy, azoospermia, and hearing loss we found a deletion compounded with
a missense variant in D-bifunctional protein, HSDB, a peroxisomal enzyme
that catalyzes beta-oxidation of very long chain fatty acids. Retrospective review
of metabolic testing from this patient revealed alterations of long- and very-long
chain fatty acid metabolism consistent with a peroxisomal disorder. is work ex-
pands the molecular basis of mitochondrial disease and has implications for clin-
ical genomics.
iv
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Introduction
T     is to link phenotype to genotype,thereby enabling basic biology research and providing direction for the
development of clinical diagnostics and therapeutics. As of January , the
molecular basis of just fewer than half of the ,Mendelian disorders described
in the Online Mendelian Inheritance in Man (OMIM) have been identiﬁed[].
Most of these associations were discovered through linkage studies followed by
positional cloning in large pedigrees[]; however, such studies require several af-

fected individuals, preferably in a multi-generation pedigree, which is not always
possible as disease often presents in singleton cases. Introduction of massively
parallel sequencing instruments [, , ], capable of generating hundreds
of millions of short reads in a single experiment, have given researchers the se-
quencing capabilities necessary to conduct genome-scale resequencing projects
on such singleton cases. In this thesis, I present the application of targeted se-
quencing on approximately  individuals with suspected mitochondrial disease
and phenotypically similar disorders. is chapter will present an introduction
to mitochondria and mitochondrial disease and then will discuss how massively
parallel sequencing can be used to gain insight into disease.
. M
Mitochondria formed when an eukaryotic progenitor engulfed an alpha-
proteobacterium[]. Inside the eukaryote, the early mitochondria began to
transfer its genome to the nucleus as it specialized into a compartment rich in
metabolic activity. Mitochondria are most well known for their role in produc-
ing cellular energy in the form of adenosine triphosphate (ATP); however, they
also play roles in the production of biosynthetic intermediates, calcium regulation
and cellular stress responses such as autophagy and apoptosis. At a macro scale,
mitochondria are a series of tubes . to . micrometer (µm) in diameter that
form a dynamically interconnected network. All cell types, except for red blood
cells, house -, mitochondria, which are actively transported to various
subcellular compartments. Populations of mitochondria are constantly fusing
and dividing. At a microscale, mitochondria have two membranes – a somewhat-
selective mitochondrial outer membrane (MOM), which encloses the intermem-

brane space, and a highly selective mitochondrial inner membrane (MIM), which
encloses the matrix.
e MIM houses the respiratory chain, a series of ﬁve macromolecular pro-
tein complexes that performs oxidative phosphorylation (OXPHOS) to produce
ATP. e ﬁrst four complexes couple electron transfer from donors (NADH and
FADH) to oxygen while pumping protons from the matrix across the MIM to the
intermembrane space, thereby generating an electrochemical gradient. Complex
V, the world’s tiniest rotary motor, uses this electrochemical gradient to gener-
ate ATP. Oxidative phosphorylation is extremely eﬃcient: aerobic catabolism of
one molecule of glucose produces - molecules of ATP while only  ATPs are
generated under anaerobic conditions. However, when cells undergo oxidative
phosphorylation they are playing with ﬁre since reactive oxygen species, capable
of causing oxidative stress, are generated by Complexes I and III[].
Mitochondria are unique in that they house an extranuclear DNA: the mtDNA.
Four of the ﬁve respiratory chain complexes, all but complex II, have components
encoded by the mtDNA. mtDNAs are .Kb circular DNAs found in - copies
in each mitochondrial matrix in a subcellular structure known as a nucleoid. e
mtDNA encodes  protein subunits of the respiratory chain,  mitochondrial
rRNAs and tRNAs. Additionalmachinery required formtDNAreplication, tran-
scription and translation are imported from the nucleus. Mitochondria DNA is
materially inherited as paternal mitochondria are eliminated through autophagy
shortly after fertilization [, ]. As mitochondria and cells contain multiple
mtDNAs, it is possible that a fractionmayharbormutations – aphenomenaknown
as heteroplasmy. Normal human cells contain dozens of heteroplasmic sites and
the frequency of heteroplasmic variants can vary considerably between diﬀerent

tissues in the same individual [].
While mitochondria have their own genome, > of mitochondrial proteins
are imported from the nucleus. e most complete mitochondrial protein inven-
tory published to date is MitoCarta[], which includes over > proteins.
A Bayesian framework was used to integrate proteomic, computational (protein
domains, induction with mitochondria, coexpression with other mitochondrial
genes, yeast homology, ancestry in R. prowazekii and targeting sequences), litera-
ture andmicroscopy data tomake a summore sensitive and speciﬁc than its parts.
It was estimated to be  complete and contain  false positives. is thesis
makes use of this molecular framework to better understand mitochondrial dis-
ease.
. M 
Mitochondrial disease is a class of devastating disorders caused by dysfunction of
the mitochondria. ey are the most common inborn errors of metabolism, with
a minimum estimated prevalence of at least  in ,[]. Illness occurs when
tissues become starved for energy, damaged by excess ROS, or accumulates nox-
ious intermediatemetabolites. Many tissue types can be aﬀected, especially those
most reliant onmitochondrial energy such as the central nervous system, skeletal
muscle, heart, endocrine organs, andkidney[]. Patients commonly presentwith
lactic acidosis, skeletal myopathy, deafness, blindness, subacute neurodegenera-
tion, intestinal dysmotility and/or peripheral neuropathy[]. A rule of thumb is
to suspect mitochondrial disease in patients with symptoms in three or more or-
gan systems without a unifying cause [], though more sophisticated diagnostic
systems exist [, ]. In addition to clinical observations, diagnosis of mito-

chondrial disease relies on laboratory observations, cerebral imaging and muscle
biopsies. Muscle tissue from biopsies is inspected histologically for a prolifera-
tion of mitochondria, which present as “ragged red ﬁbers”, and biochemically for
respiratory chain function. is testing can run up to , and often returns
ambiguous ﬁndings, partially due to lab-to-lab variabilities[, ]. Patients can
go through a long diagnostic journey before mitochondrial disease is suspected
and many cases of suspected mitochondrial disease may actually be due to a re-
lated disorder. With the exception of disease due to CoQ deﬁciency, no proven
cures exist and treatments focus on relieving symptoms[].
While inﬂuenced by environmental factors, most cases of mitochondrial dis-
eases are believed to caused by genetic factors. Genetically, mitochondrial dis-
eases exhibit maternal (mitochondrial), autosomal dominant, autosomal reces-
sive and X-linked modes of inheritance. Mutations in  mitochondrial and 
nuclear genes have been implicated in mitochondrial disease []. mtDNA mu-
tations may be homoplasmic, being present in all molecules, or heteroplasmic,
being present in only a fraction. Patients with heteroplasmic mutations present
with symptoms only when heteroplasmy exceeds a certain level, a phenomenon
known as the threshold eﬀect. ese mitochondrial mutations have been more
thoroughly studied than those of nuclear localization since the .KB mtDNA
is much easier to sequence than the full human genome. e majority of mito-
chondrial disease cases (-) are believed to be due to nuclear mutations[],
yet as of  only half of patients with complex I disease could be diagnosed
with the current list of Mitochondrial disease genes []. Nuclear proteins that
cause mitochondrial disease are not just found in structural subunits of the respi-
ratory chain complexes, but also include proteins that fall in a variety of processes

necessary for mitochondrial formation and function including those essential for
mtDNA replication, transcription, RNA-processing, translation, assembly factors
and mitochondrial membrane dynamics and composition.
Historically, clinical genetic evaluation of patients with mitochondrial disease
has been limited to sequencing of the mtDNA or a handful of candidate genes,
but it is hard to prioritize candidate genes as there is often a poor link between
genotype and phenotype in mitochondrial disease. A recent literature review of
 patients with nuclear encoded complex I deﬁciency found that most children
had a severe multi-system disease with prominent neurological involvement, but
actual symptoms and onset varied and no clear genotype-phenotype correlations
were found[]. mtDNA mutations are also diﬃcult to interpret as some show
variable levels of penetrance. For example, the majority of families with the mi-
tochondrial disease of Leber’s hereditary optic neuropathy are often homoplastic
for mtDNA mutations; however, only a subset of individuals in these families de-
velops disease, leading to the hypothesis that there are additional nuclear factors
to be identiﬁed[].
. DNA S   
Over the past ﬁve years, as human genome sequencing transformed from a re-
search grade eﬀort costing ,[] to a clinical test orderable by doctors
for under ,, it has become practical for researchers to sequence individual
patients. is price reduction was enabled by the creation of massively-parallel
next generation sequencing (NGS) instruments, which were spurred by a series
of grants that succeeded the sequencing of the human genome [] and hope to
reduce costs to , and beyond. While the ﬁrst generation sequencing instru-

ments used to sequence the human genome were cable of generating hundreds
of concurrent sequences of ~ bases, second-generation sequencing instru-
ments are cable of generating data from one or both ends of hundreds of millions
of shortDNA fragments in parallel, though these sequences aremuch shorter with
read lengths of -bp. To discover variants, these reads are ﬁrst mapped to a
reference genome. Single base pair changes, referred to as single-nucleotide vari-
ants (SNVs), and small insertions and deletions (indels) are detected by evaluation
reads that overlap each reference base. Larger variants, referred to as structural
variants, also exist and are discussed more in Chapter .
As it is still somewhat expensive to conduct whole genome sequencing of all 
billion bases in a humanhaploid genome,many researchers opt instead to perform
exome sequencing, which costs a tenth to a third asmuch. In this form of targeted
sequencing, DNA is processed to enrich for coding DNA sequences before being
placed on a sequencer. A variety of selection methods exist[, ], but most
projects, including those described in this thesis, use a liquid phase capture strat-
egy known as hybrid selection []. Early exome designs targeted the Mb (~
of the genome) deﬁned by the Consensus CDS (CCDS) []; however this target
only accounts for about  of the , human genes. Larger targets based on
GENCODE Encyclopedia of genes have since been developed []. e ﬁrst study
to show that exome sequencing could identify a known candidate gene was per-
formed in  unrelated cases of Freeman-Shlend syndrome, who were shown to all
have mutations inMYH[]. Since then, there has been a ﬂurry of Mendelian
disease genes discovered through exome sequencing [], including many that
cause mitochondrial disease [, , , , –, , , , , ].
Exome sequencing is not perfectly suited for a cohort of patients with mito-

chondrial diseases. First, mtDNA is not reliably captured by a standard exome
target and and CCDS target lacks coverage for several genes inMitoCarta[]. Ad-
ditionally, > ofmitochondrial disease genes are localized in themitochondria,
making sequencing of an entire exome seem ineﬃcient. In this thesis, we present
an alternative: MitoExome sequencing. We target <Mb of DNA that consists of
the mtDNA and exons from over , nuclear genes. ese nuclear genes come
from the MitoCarta inventory, but also include additional candidate mitochon-
drial genes and known disease genes that cause diseases phenotypically similar to
mitochondrial disease.
. T 
is thesis begins with Chapter , which introduces MitoExome sequencing and
benchmarks its performance on  patients with infantile mitochondrial disease.
A case study showing how discovery of a new disease can lead to new biology can
be found in Chapter . Chapter  describes eﬀorts to increase the diagnostic yield
by attempting to call large ampliﬁcations and deletions. is thesis concludeswith
a summary of implications and future directions in Chapter .

2
Molecular diagnosis of infantile
mitochondrial disease with targeted
next-generation sequencing
A  - sequencing (NGS) promise to facilitate diag-nosis of inherited disorders. Although in research settings NGS has pin-
pointed causal alleles using segregation in large families, the key challenge for clin-
ical diagnosis is application to single individuals. To explore its diagnostic use, we

performed targeted NGS in  unrelated infants with clinical and biochemical evi-
dence of mitochondrial oxidative phosphorylation disease. ese devastating mi-
tochondrial disorders are characterized by phenotypic and genetic heterogeneity,
with more than  causal genes identiﬁed to date. We performed “MitoExome”
sequencing of themitochondrial DNA (mtDNA) and exons of ~ nuclear genes
encoding mitochondrial proteins and prioritized rare mutations predicted to dis-
rupt function. Because patients and healthy control individuals harbored a com-
parable number of such heterozygous alleles, we could not prioritize dominant-
acting genes. However, patients showed a ﬁvefold enrichment of genes with two
such mutations that could underlie recessive disease. In total,  of  () pa-
tients harbored such recessive genes or pathogenic mtDNA variants. Firm diag-
noses were enabled in  patients () who had mutations in genes previously
linked to disease. irteen patients () hadmutations in nuclear genes not pre-
viously linked to disease. e pathogenicity of two such genes,NDUFB and AGK,
was supported by complementation studies and evidence from multiple patients,
respectively. e results underscore the potential and challenges of deployingNGS
in clinical settings.
. I
Advances in next-generation sequencing (NGS) technology are facilitating the dis-
covery of new disease genes and promise to transform the routine clinical diag-
nosis of inherited disease. Since the ﬁrst reports in  [, ], NGS has
aided in the discovery of more than  new disease genes in research settings.
Although sequence-based clinical diagnosis has long been available for individual
genes, NGS could be particularly useful for conditions characterized by genetic

heterogeneity, where individual genes cannot be readily prioritized for traditional
sequencing. e success of NGS for clinical use, however, hinges on distinguish-
ing the small number of pathogenic alleles from the thousands of DNA variants
present in each person. When DNA is available from large aﬀected families or
from individuals with a closely related phenotype, variants have been successfully
prioritized on the basis of segregation with disease. However, it is not clear how
useful NGS-based diagnostics will be in themore typical clinical scenario where an
individual has no clear family history of disease andwhere themode of inheritance
is ambiguous.
Human oxidative phosphorylation (OXPHOS) disease represents a challenging
class of disorders that could beneﬁt tremendously if sequence-based tests could
provide accurate diagnosis. Inherited defects in OXPHOS aﬀect at least  in 
live births [] and are characterized by a biochemical defect in the respiratory
chain. OXPHOS disease is clinically heterogeneous because it can present early
in infancy or in adulthood, can be severe or mild in its presentation, and typi-
cally aﬀects multiple organ systems. Clinical manifestations can include, but are
not limited to, myopathy, lactic acidosis, seizures, ataxia, peripheral neuropathy,
blindness, deafness, gastrointestinal dysmotility, liver failure, and bone marrow
dysfunction[]. OXPHOS disease can showmaternal, recessive, dominant, or X-
linked inheritance, although most cases are sporadic and have no obvious family
history [, ]. Biochemical diagnosis typically requires invasive biopsies and
even then can be inconclusive.
Genetically, OXPHOS disease can be caused by mutations either in the mito-
chondrial DNA (mtDNA) or in the nuclear genome. It is possible to routinely re-
sequence the mtDNA, but lesions in this tiny genome likely account for no more

than  to  of all childhood cases [, ]. A recent review listed  nu-
clear disease genes, identiﬁed largely through pedigree analysis, with up to  new
OXPHOS disease genes described each year []. Most involve recessive, loss-
of-function alleles, although nine genes can harbor dominant-acting mutations
(POLG,POLG,Corf, RRMB,SLCA,OPA, CYCS,MFN, andHSPD) [].
Individual sequence-baseddiagnostic tests are readily available for eachof  genes
[] and, more recently, NGS gene panels [, ]; however, pleiotropy makes it
diﬃcult for clinicians to predict which speciﬁc genes may be mutated in a given
case []. Moreover, the known disease genes likely account for only a fraction of
the total genetic burden of these disorders []. Given that  of the known nu-
clear disease genes encode mitochondrial-localized proteins (Supplementary Ma-
terial in Appendix A), the full set of ~ genes encodingmitochondrial proteins
represents strong candidates for OXPHOS disease []. e extensive locus het-
erogeneity, allelic heterogeneity, and pleiotropy of OXPHOS disease, combined
with the availability of a focused set of ~ high-conﬁdence candidate genes
encoding the known mitochondrial proteome, make OXPHOS disorders an ideal
application area for sequence-based diagnostics. ree recent studies reported the
technical feasibility of sequencing several hundred of these genes [, , ],
and NGS diagnostic tests are newly available for panels of disease-related genes
[, ]. We performed targetedNGS to capture and sequence the entiremtDNA
and the exons of the ~ genes encoding themitochondrial proteome (the “Mi-
toExome”). After benchmarking the performance on several DNA samples, we ap-
plied MitoExome sequencing to  unrelated patients with clinical and biochemi-
cal evidence of infantile OXPHOS disease in whom a molecular diagnosis was not
previously available (Table .).

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.. ME   
We targeted for sequencing the entire mitochondrial genome and all coding exons
of  nuclear genes encoding mitochondrial proteins based on the MitoCarta
inventory [] (Table S available on the attached CD). ese regions were en-
riched using hybrid selection and then sequenced on an Illumina GAII. For each
individual, we generated ~ billion bases of sequence, which yielded an average
coverage of ~× at each targeted nuclear base and ~,× at each mtDNA
base (Table .). On average,  of targeted bases were covered and  of tar-
geted bases exceeded the × coverage threshold required for conﬁdent analysis,
deﬁned as  power to detect a variant (Table .).
Table 2.2: MitoExome sequencing statistics. *Median values per patient, with
range across patients indicated in brackets. † Excluding reads with ambiguous align-
ment
Targeted DNA Targeted DNA* Targeted DNA*
 gene loci  
target size (bp) ,, ,
coverage†
mean coverage  [–] , [,-,]
 target bp covered ≥X  [–]  []
 target bp covered ≥X  [–]  []
 target bp covered ≥X  [–]  []
 variants compared to reference DNA  [–]  [–]
 rare  [–]  [–]
 rare, protein-modifying  [–]  [–]
 genes with  rare, protein-modifying alleles  [–] NA
e accuracy and reproducibility of MitoExome variant detection was assessed
using DNA obtained from the parents and daughter of a family with indepen-

dent sequence data available through HapMap []. Detection of nuclear single-
nucleotide variants (SNVs) was  sensitive and  speciﬁc based on  and
 sites genotyped using independent technology. Speciﬁcally, there was 
genotype concordance at heterozygous sites,  concordance at homozygous
sites, and . concordance at sites with at least  reads. Similarly, nuclear SNV
detection was  sensitive based on  variant sites detected by whole-genome
sequencing of these samples (. concordance at sites with at least  reads).
Two technical replicates of MitoExome sequencing showed  concordance at
variant sites, consistent with the reported sensitivity. mtDNA SNV detection was
 sensitive and  speciﬁc based on ﬁve patient samples for which indepen-
dent data were available.
MitoExome sequencing was next applied to whole-genome ampliﬁed DNA ob-
tained from  unrelated patients who fulﬁlled the clinical and biochemical crite-
ria for OXPHOS disease before  years of age (Table .). ese patients included
 from consanguineous families and  additional patient with an aﬀected fam-
ily member, although none of these families were large enough to identify a sin-
gle locus by a traditional mapping approach. Each sequenced individual harbored
about  nuclear SNVs,  small nuclear insertions or deletions (indels), and 
mtDNA variants compared to the reference human genome (Table . and Table
S available on the attached CD).
.. V 
e key challenge for interpreting sequence data for molecular diagnosis is to dis-
tinguish causal alleles from the thousands of variants present in each individual.
As we focused on rare, devastating clinical phenotypes, we hypothesized that the

underlying causal variants would be uncommon in the general population, disrup-
tive to protein function, and would either be inherited in an autosomal recessive
fashion fromunaﬀected carrier parents or be de novo, dominant-actingmutations.
We therefore highlighted all nuclear variants that were rare and predicted to be
protein-modifying (Materials and Methods), as well as all variants previously as-
sociatedwith disease in theHumanGeneMutationDatabase (HGMD) (Table .).
If rare, protein-modifying variants are enriched for causal alleles, we would ex-
pect increased prevalence in patients compared to healthy individuals. erefore,
we analyzed the MitoExome regions in  healthy individuals of European an-
cestry with available whole-exome sequence data. To avoid overestimating patient
variants, we limited this comparison to the  patients from nonconsanguineous
families and to MitoExome regions well covered in all individuals ( of all au-
tosomal coding exons, see Materials and Methods). Genes containing only a sin-
gle rare, protein-modifying variant showed only a .-fold enrichment in patients
compared to controls (P = .), and this subtle enrichment is likely caused by
greater ethnic diversity in patients (Fig. .A and Fig. A.). However, we observed
a marked .-fold enrichment of genes containing two such prioritized alleles in
patients compared to controls (P =  ) (Fig. .A and Materials and Meth-
ods). ere was no enrichment observed in the  auxiliary genes sequenced
(that had only weak evidence of mitochondrial localization), suggesting that the
enrichment is not due to population stratiﬁcation (Fig. .A). Forty-ﬁve percent
of all nonconsanguineous cases contained mitochondrial genes with two priori-
tized variants compared to only  of controls (.-fold enrichment, P =  )
(Fig. .B). us, the background rate of rare, predicted deleterious heterozygous
variants makes it diﬃcult to spotlight dominant-acting, heterozygous causal al-

Figure 2.1: Enrichment of prioritized variants in cases compared to healthy
individuals. (A) Mean number of genes containing rare, protein-modifying alle-
les in cases and healthy controls within the 1034 mitochondrial genes and the 347
auxiliary genes sequenced. Error bars indicate SE. (B) Percent of cases and con-
trols containing prioritized mitochondrial genes (red), deﬁned as harboring two rare,
protein-modifying alleles. (C) Percent of cases and controls containing prioritized mi-
tochondrial genes, excluding variants with allele frequency of >0.005 in either cases
or controls, with enrichment in cases versus controls displayed above. Analysis was re-
stricted to regions with sequence coverage in all individuals and to the 31 cases from
nonconsanguineous families.
leles from individual DNA samples. However, the excess of genes harboring two
prioritized variants provides a signal to distinguish recessive variants. erefore,
we prioritized only variants consistent with a recessivemode of pathogenesis, and
denoted “prioritized genes” as those containing two such alleles.
We additionally prioritized two classes of mtDNA variants: variants annotated
as pathogenic inMITOMAP [] at greater than heteroplasmy (as estimated
by sequence reads) [], and structural deletions and rearrangements as detected
by de novo mtDNA assembly. Detection of heteroplasmic variants via deep se-
quencing was previously validated on the basis of mixing experiments [].
For the nine genes known to harbor dominant mutations in OXPHOS disease,
we carefully evaluated all rare, protein-modifying variants and all variants that
were reported as pathogenic in HGMD. As described in the Supplementary Mate-

rial, none of the six such variants appeared to be dominant mutations associated
with the observed patient phenotypes.
.. E     
We note that the ﬁvefold enrichment of prioritized genes in cases compared to
controls is likely to be a conservative estimate, especially as databases of allele fre-
quencies improve. Indeed, many prioritized variants showed greater than .
allele frequency in the  control samples. Whenwe excluded variants exceeding
. allele frequency from cases and  controls (similar to exclusion criteria
based on  genomes and dbSNP thresholds), we observed a .-fold enrich-
ment in nonconsanguineous cases versus controls (P =  ) (Fig. .C). is
corresponded to a marked .-fold enrichment (P =  ) speciﬁcally within
the  established disease-related genes [] and .-fold enrichment (P =  
) within the remaining mitochondrial genes (Fig. .C).us, the  infan-
tile patients are enriched for prioritized variants in both known pathogenic genes
and candidate genes not previously linked to disease.
.. P    
Of the  patients with severe OXPHOS disorders,  () harbored at least
one “prioritized gene” or mtDNA variant:  () of these were in known, nu-
clear OXPHOS disease–related genes,  () were in nuclear genes not pre-
viously linked to disease, and  patient () harbored a large mtDNA deletion
(Fig. .A). e remaining  () patients lacked prioritized genes or mtDNA
variants. Most prioritized genesharboredmissense changes at amino acid residues
highly conserved across evolution (Fig. .B). Because there was about ﬁvefold en-

Figure 2.2: Prioritized variants in 42 patients with OXPHOS disease. (A)
Forty-two patients categorized by the presence of prioritized genes (red). The gene
names are listed alphabetically at right, with parentheses indicating genes prioritized
in two unrelated patients, and triangle indicating support of pathogenicity. (B) Fifty-
two prioritized alleles, categorized by type of protein modiﬁcation.
richment in patients with prioritized genes compared to controls, we can estimate
that about  of the  patients () will contain causal variants in prioritized
genes. Determining which of the prioritized DNA variants are actually causal will
require additional experimental evidence.
.. M    DNA
rough de novo assembly of the mtDNA (Materials and Methods), we discovered
a .-kb deletion in the mitochondrial genome in patient P (Fig. .A). is pa-
tient presented with progressive developmental delay and regression, failure to
thrive, microcephaly, lactic acidosis, and death after a sudden metabolic and neu-
rological decompensation. Muscle biopsy showed ragged red ﬁbers and reduced
cytochrome c oxidase (COX) staining in aﬀectedﬁbers. edeletion (m._
delwith imperfect tandemrepeats at both ends) has beenpreviously reported
[] and was present in  of sequence reads at this locus. e deletion was
conﬁrmed by quantitative polymerase chain reaction (qPCR) to be at  het-

Figure 2.3: mtDNA deletion in patient P33. (A) Schematic diagram of mtDNA
indicates deletion (black arc) relative to position 0/16,569 (black triangle). Arrows
indicate LR-PCR primers. (B) mtDNA sequence coverage in 50-bp windows. Inset
shows Sanger electropherogram of breakpoint. (C) Gel electrophoresis of LR-PCR
amplicon displays a 14,939-bp fragment in control DNA and 7681-bp fragment in
P33, along with marker II (Roche) and mtDNA from individuals with conﬁrmed single
and multiple deletions.
eroplasmy in genomic DNA from aﬀected muscle tissue. Because of mtDNA pro-
liferation ( compared to control), the actual amount of nondeleted mtDNA
present in muscle of this patient was  of control. e deletion was conﬁrmed
by long-range PCR (LR-PCR) (Fig. .C), and the breakpoints were mapped by
Sanger sequencing (Fig. .B). us, MitoExome sequencing enables simultane-
ous detection of mtDNA point mutations and deletions.
.. M 

Ten patients harbored recessive mutations in eight genes previously shown to
cause OXPHOS disease: ACAD [, ], POLG [, ], BCSL [], COXB
[], GFM [], TSFM [], AARS [], and TYMP [] (Fig. .A). All such
variants were conﬁrmed through Sanger sequencing. We established compound
heterozygosity via sequencing familialDNA, complementaryDNA (cDNA), cloning,

ormolecular haplotyping [] because short sequence reads do not typically pro-
vide the ability to determine whether variants are in cis or trans.
With additional experiments, we established a ﬁrm genetic diagnosis for nine
of these patients (Table .). ese methods included the demonstration that the
detected alleles segregated with disease in a family, that they were rare in controls,
and/or that they caused reduced cellular abundance of full-length mRNA tran-
scripts, protein products, or OXPHOS subunits and assembly factors (Table .
and Materials and Methods). e enzyme ACAD [, ], recently linked to
complex I deﬁciency [Mendelian Inheritance inMan (MIM) ], wasmutated
in a male infant with isolated complex I deﬁciency and lethal infantile mitochon-
drial disease (Fig. A.). A female infant with encephalopathy and clear complex
I deﬁciency with less marked deﬁciency of complexes III and IV harbored previ-
ously reported causal mutations in POLG [, ], which encodes the mtDNA
polymerase and is themost commonlymutated nuclear gene underlying OXPHOS
disease () (Fig. A.). e complex III assembly factor gene BCSL [] which is
the most commonly mutated gene in complex III deﬁciency (MIM ) [],
was mutated in an infant girl with complex III deﬁciency (Fig. A.). Complex
IV subunit COXB [] was mutated in a boy with neonatal onset of mito-
chondrial encephalopathy, metabolic acidosis, and complex IV deﬁciency (MIM
) (Fig. A.). e protein GFM (MIM ) [], which is required for
translational elongation of mtDNA-encoded proteins, was mutated in two unre-
lated patients withmitochondrial encephalopathy presenting within the ﬁrst year
of life (Fig. A.). A second elongation factor, TSFM [], was mutated in one pa-
tient with combined OXPHOS deﬁciencies (MIM ) and in an unrelated pa-
tient with cardioencephalomyopathy (Fig. A.). A stillborn fetus with mitochon-

drial myopathy harbored one new and one previously reported causal variant in
the mitochondrial translational protein AARS, which was recently shown to un-
derlie fatal infantile cardiomyopathy (MIM )[] (Fig. A.).
Although in all nine cases theMitoExome genetic diagnosis was consistentwith
the patient phenotype, the clinical presentation alone was never speciﬁc enough
to suggest the underlying gene as the most likely candidate for an available gene-
based sequence diagnostic test, except perhaps for BCSL. In the remaining th
case, the compound heterozygous TYMPmutations in patient P do not ﬁt with
the clinical presentation, complex III defect, or familial consanguinity, and it is
possible that homozygousmutations in candidate genesMTCH or Corfmay
prove to be causal.

Ta
bl
e
2.
3:
Su
pp
or
to
fm
ol
ec
ul
ar
di
ag
no
sis
in
13
pa
tie
nt
s.
*In
dic
at
es
ge
ne
sp
rev
iou
sly
as
so
cia
ted
wi
th
OX
PH
OS
dis
ea
se
.A
bb
re-
via
tio
ns
:c
mp
d
he
t,
co
mp
ou
nd
he
ter
oz
yg
ou
s;
ho
m.
,h
om
oz
yg
ou
s;
he
t,
he
ter
oz
yg
ou
s;
mu
t,
he
ter
op
las
mi
cm
ut
an
tl
oa
d.
ID
D
is
ea
se
su
b-
ty
p
e
G
en
e
T
yp
e
M
u
ta
ti
on
s
A
C
M
G
ca
te
-
go
ry
[

]
Su
p
p
or
t
of
p
at
h
o
ge
n
ic
it
y
P

co
m
pl
ex
I
de
ﬁ
ci
en
cy
(M
IM
:


)
*A
C
A
D

cm
pd
h
et
c.

G
>
C
,
p.
A

P
[
]

co
n
se
rv
at
io
n
,
pr
ot
ei
n
de
gr
ad
a-
ti
on
c.

T
>
A
,
p.
I
N

P

co
m
pl
ex
I
de
ﬁ
ci
en
cy
(M
IM
:


)
*P
O
LG
cm
pd
h
et
c.


G
>
A
,
p.
G

S
[

]

c.

C
>
T,
p.
R

W
[ 
]

P

co
m
pl
ex
I
de
ﬁ
ci
en
cy
(M
IM
:


)
N
D
U
FB

h
om
.
c.

T
>
C
,
p.
W

R

M
ot
h
er
ca
rr
ie
r,
n
o
de
le
ti
on
or
is
op
ar
en
ta
l
di
so
m
y
de
te
ct
ed
by
A
ﬀ
y
.
M
&
Il
lu
m
in
a

K
ar
-
ra
ys
,p
ro
te
in
de
gr
ad
at
io
n
,c
on
se
r-
va
ti
on
,c
or
re
ct
io
n
st
ud
ie
s
P

co
m
pl
ex
II
I
de
ﬁ
ci
en
cy
(M
IM
:


)
*B
C
S
L
cm
pd
h
et
c.

C
>
T,
p.
R

X
[ 

]

co
n
se
rv
at
io
n
,
m
R
N
A
an
d
pr
ot
ei
n
de
gr
ad
at
io
n
c.

C
>
T,
p.
R

C

C
on
ti
nu
ed
on
ne
xt
pa
ge

Ta
bl
e
.

–
C
on
ti
nu
ed
fr
om
pr
ev
io
us
pa
ge
ID
D
is
ea
se
su
b-
ty
p
e
G
en
e
T
yp
e
M
u
ta
ti
on
s
A
C
M
G
ca
te
-
go
ry
[

]
Su
p
p
or
t
of
p
at
h
o
ge
n
ic
it
y
P

co
m
pl
ex
IV
de
ﬁ
ci
en
cy
(M
IM
:


)
*C
O
X
B

h
om
.
c.

A
>
C
,
p.
T

P

pr
ot
ei
n
de
gr
ad
at
io
n
,f
am
ily
se
gr
e-
ga
ti
on
P

co
m
pl
ex
IV
de
-
ﬁ
ci
en
cy
*G
FM

cm
pd
h
et
c.

d
el
T,
p.
E

N
fs
X


m
R
N
A
de
gr
ad
at
io
n
,
pr
ot
ei
n
de
gr
ad
at
io
n
,f
am
ily
se
gr
eg
at
io
n
c.


C
>
T,
p.
R

C

P

co
m
bi
n
ed
de
ﬁ
ci
en
cy
(M
IM
:


)
*G
FM

cm
pd
h
et
c.

d
el
T,
p.
E

N
fs
X


m
R
N
A
de
gr
ad
at
io
n
,
pr
ot
ei
n
de
gr
ad
at
io
n
m
at
er
n
al
ca
rr
ie
r
c.

d
el
T
c.

A
>
G
,
p.
K

E

P

co
m
bi
n
ed
de
ﬁ
ci
en
cy
(M
IM
:


)
*T
SF
M
h
om
.
c.

C
>
T,
p.
R

W
[ 

]

fa
m
ily
se
gr
eg
at
io
n
P

co
m
bi
n
ed
de
ﬁ
ci
en
cy
(M
IM
:


)
*T
SF
M
h
om
.
c.

C
>
T,
p.
R

W
[

]

fa
m
ily
se
gr
eg
at
io
n
P

co
m
bi
n
ed
de
ﬁ
-
ci
en
cy
m
tD
N
A
de
le
ti
on


m
ut
m
.

_


d
el


[

]

qP
C
R
,L
R
-P
C
R
an
d
se
qu
en
ci
n
g
P

m
tD
N
A
de
pl
e-
ti
on
*A
A
R
S
cm
pd
h
et
c.

G
>
A
,
p.
R

H

co
n
se
rv
at
io
n
,
pr
ot
ei
n
de
gr
ad
a-
ti
on
C
on
ti
nu
ed
on
ne
xt
pa
ge

Ta
bl
e
.

–
C
on
ti
nu
ed
fr
om
pr
ev
io
us
pa
ge
ID
D
is
ea
se
su
b-
ty
p
e
G
en
e
T
yp
e
M
u
ta
ti
on
s
A
C
M
G
ca
te
-
go
ry
[

]
Su
p
p
or
t
of
p
at
h
o
ge
n
ic
it
y
c.


C
>
T,
p.
R

W
[ 
]

P

m
yo
pa
th
ic
m
tD
N
A
de
pl
et
io
n
(M
IM
:


)
A
G
K
cm
pd
h
et
c.

+
T
>
C
,
p.
K

Q
fs
X


in
de
pe
n
de
n
t
m
ut
at
io
n
s
in

pa
-
ti
en
ts
c.


T
>
A
,
p.
Y

X

P

m
yo
pa
th
ic
m
tD
N
A
de
pl
et
io
n
(M
IM
:


)
A
G
K
h
om
.
c.


+
G
>
T,
p.
S

E
fs
X


in
de
pe
n
de
n
t
m
ut
at
io
n
s
in

pa
-
ti
en
ts
,f
am
ily
se
gr
eg
at
io
n

.. M   
About one-third of patients harbored prioritized DNA sequence variants in genes
never before linked to OXPHOS disease. In total,  such candidate disease genes
were identiﬁed in  patients (Fig. .A and table S) after excluding mutations
that were not compound heterozygous (MRPL) andmutations that did not seg-
regate with disease in available familial DNA (COX, FAMA). Our collec-
tion of candidate genes is likely greatly enriched for new, bona ﬁde mitochon-
drial disease genes, but additional proof of pathogenicity is required. Onemethod
is to identify independent mutations of the same gene in unrelated individuals
presenting with exquisitely similar phenotypes, as was recently shown for Miller
[], Kabuki [], and Bartter [] syndromes. A second deﬁnitive method is
to complement a cellular defect present within patient cells by introducing a wild-
type copy of the locus, either through cybrid fusions for mtDNA defects [] or
throughoverexpressionof anuclear gene []. Weobtained support of pathogenic-
ity for two of the new disease genes, as described below.
.. AGK       DNA -

One new candidate gene, acylglycerol kinase (AGK), had recessive mutations in
two unrelated patients. is protein [also known as multisubstrate lipid kinase
(MuLK)] phosphorylates monoacylglycerols and diacylglycerols to lysophospha-
tidic acid and phosphatidic acid, respectively []. e two unrelated patients each
presented with severe myopathy, combined complex I, III, and IV deﬁciency, bi-
lateral cataracts, and severe mtDNA depletion in skeletal muscle ( and  of
normal). Detailed clinical histories are available in the Supplementary Material.

Currently, only two genes are known to underlie the myopathic form of mtDNA
depletion [] [TK/MIM  [] and RRMB/MIM  []], and
coding mutations in both these genes were excluded. Our two unrelated patients
harbored three severe mutations in AGK (Fig. . and Fig. A.): patient P har-
bored a homozygous splice variant that caused a shortened transcript with a pre-
mature termination codon (c.+G>T, p.SEfsX), and patient P har-
bored a compound heterozygous nonsense variant (p.YX) and splice variant
that caused a shortened transcriptwith apremature termination codon (c.+T>C,
p.KQfsX), inherited respectively from her mother and father. All mRNAs
were stable and not aﬀected by nonsense-mediated decay. All three mutations
would cause deletion of a C-terminal region that is highly conserved across evolu-
tion and thus likely to be important for proper protein function, especially because
it contains the conserved C domain from related sphingosine-type kinases []
(Fig. .). We screened for coding AGK mutations in eight additional individuals
with myopathic mtDNA depletion but detected no further mutations.
Our identiﬁcation of independent, likely deleterious mutations in AGK in pa-
tients with myopathic mtDNA depletion suggests that AGK is a new locus under-
lying this syndrome andmay oﬀer a link between lipidmetabolism and the control
of mtDNA copy number.
.. E    NDUFB
e complex I subunit NDUFB was mutated in patient P, a girl from a noncon-
sanguineous family with complex I deﬁciency and lethal infantile mitochondrial
disease. She harbored an apparently homozygous c.T>C (p.WR) mutation.
e p.W residue is highly conserved (conserved in  of  vertebrates) and

Figure 2.4: Patient mutations in acylglycerol kinase (AGK). Schematic dia-
gram shows protein structure with the location of truncating mutations in unrelated
patients P41 and P42 shown in red and a box indicating the diacylglycerol kinase
catalytic domain. Conservation of C-terminal region is shown below, with identical
residues shaded and the C5 domain shared with yeast sphingosine kinases underlined.

lies adjacent to an important lysine residue that undergoes N-acetylation within
the N terminus (Fig. A.). Sanger sequencing identiﬁed the proband’s mother
as a heterozygous carrier for this mutation. Paternal DNA was unavailable for
testing. To assess possible DNA deletions or uniparental isodisomy, we analyzed
proband and maternal DNA using single-nucleotide polymorphism (SNP) arrays.
No large deletions were evident, and isodisomy of chromosome  was excluded on
the basis of the SNPduo identity by state algorithm []. However, the CNVPar-
tition v.. algorithm (Illumina) detected a .-Mb long contiguous stretch of
homozygosity (LCSH) encompassing NDUFB in the proband’s DNA (Fig. A.).
ematernal sample did not show statistically signiﬁcant evidence of LCSH. Anal-
ysis of the patient’s ﬁbroblast cDNA (with and without cycloheximide) showed a
single stable transcript of expected size, indicating that themutation did not alter
mRNA splicing or the presence of any small indels below the detection range of
the cytogenetic arrays.
We next performed a complementation experiment to assess whether the in-
troduction of wild-type cDNA into subject ﬁbroblasts rescued the defect in com-
plex I activity. Fibroblasts from this individual showed a strong complex I defect,
with ~ residual complex I activity when assayed by spectrophotometric en-
zyme assay and< residual complex I activity when assayed by dipstick enzyme
assay. Using a lentiviral expression system, we transduced subject ﬁbroblasts with
wild-type cDNA. Expression of wild-type NDUFB rescued complex I activity and
protein levels in ﬁbroblasts from subject P but not from a previously diagnosed
patient with complex I deﬁciency, who had pathogenicmutations in Corf[]
and vice versa (Fig. .), establishingNDUFB as the causal gene in this case. is
is the  nuclear encoded complex I subunit gene in which mutations have been

shown to cause complex I deﬁciency in humans.
. D
We performed MitoExome sequencing of the entire mtDNA and exons of 
nuclear genes encoding mitochondrial proteins, including all  nuclear OXPHOS
disease–related genes that were reviewed recently []. We applied MitoExome
sequencing to  unrelated patients with a spectrum of early-onset OXPHOS dis-
orders who lacked molecular diagnoses. Notably, we did not know what percent
of unsolved OXPHOS cases would be expected to be due to mutations in estab-
lished loci, because, to our knowledge, no study had sequenced even the  known
disease-related genes in a collection of cases. We found that only  of unsolved
cases were due tomutations in the known disease loci (including onemtDNAdele-
tion and nine nuclear gene defects shown in Fig. .), highlighting the locus het-
erogeneity of OXPHOS disease. A further  of patients harbored rare, protein-
modifying, recessive variants in candidate genes not previously linked toOXPHOS
disease. Given that such variants exhibit ﬁvefold enrichment in cases over back-
ground, they are likely enriched for truly causal alleles. We performed comple-
mentation experiments to ﬁrmly establish pathogenicity for NDUFB in complex
I deﬁciency, and based on independent mutations in P and P, we suggest a
new link between the gene AGK and myopathic mtDNA depletion through an un-
known mechanism.
Recessive mutations in  additional genes, not previously linked tomitochon-
drial OXPHOS disease, were identiﬁed. Formal proof of pathogenicity will be es-
tablished by cDNA complementation experiments in cellular models or patient
ﬁbroblasts [], when such cells exhibit an OXPHOS defect, or by detecting inde-

Figure 2.5: NDUFB3 complementation of complex I defects in subject P3
ﬁbroblasts. (A) Bar plots show complex I (CI) activity, normalized by complex IV
(CIV) activity, in ﬁbroblasts from patient P3, a healthy control individual, and an un-
related patient with complex I deﬁciency because of a C8orf38 mutation P(C8orf38).
Enzyme activity was measured before and after transduction with wild-type C8orf38
or NDUFB3 mRNA. Data are means of three biological replicates ± SEM. *P <
0.001, Student’s t test. (B) Western blot shows protein expression of complex I, com-
plex IV, and complex V (CV) as the loading control.

pendent mutations in individuals with a similar phenotype. We estimate that 
of these  genes will prove to be bona ﬁde disease genes. ese candidates are
particularly exciting because until recently such discoveries generally required fa-
milial forms of disease to narrow down the search region. Some of the candidate
genes have established roles in OXPHOS biology, consistent with the enzyme de-
fect found in the relevant patient (for example, UQCR, LYRM, and EARS),
whereas most of the candidates encode poorly characterized proteins that have
never before been linked to OXPHOS and will reveal fundamentally new biochem-
ical insights (for example, Corf, Corf, and AKRB).
is pilot study showed that about half of the  sequenced patients lacked
“smoking gun” prioritized variants. We can envision at least ﬁve possible expla-
nations. First, we may have missed the causal variants because of a technical lack
of sensitivity. Although we detected more than  of SNVs present in the Mi-
toExome, there is an unknown sensitivity for indels and exon deletions because
of a lack of training data. Second, the causal variant may have been located in a
gene that we did not target with MitoExome sequencing. Although possible, this
explanation seems less likely because linkage and homozygosity mapping strate-
gies to date have found that  of causal genes encode mitochondrial proteins.
ird, the causal variant may be located in a nontargeted intronic or regulatory
region. Although these are likely to exist, no robust methods are available yet for
interpreting such variants. Fourth, and perhaps most likely, our stringent ﬁlters
may have rejected the truly causal variant. For example, de novo dominant alleles
[], acting through gain of function or haploinsuﬃciency, were not prioritized
because, without parental DNA, these alleles are diﬃcult to distinguish from the
high heterozygote burden of apparently deleterious alleles in healthy individuals.

Similarly, it is diﬃcult to distinguish benign from pathogenic mtDNA variants
[]. By applying MitoExome sequencing to parental DNA, such de novo alleles
may be identiﬁed in the future []. Finally, and potentially most interesting,
our assumptions on the genetic architecture of OXPHOS disease may be inaccu-
rate. Nearly all of the nuclear genes discovered to date correspond to Mendelian
syndromes, characterized by strong, highly penetrant alleles. It is possible that
many of the sporadic cases of OXPHOS disease in our cohort are due to the com-
bined action of multiple “weak” alleles, each with incomplete penetrance.
Our study underscores the need for clinical standards for interpretation of ge-
netic variants to evolve as NGS is applied more widely. First, current guidelines
for interpreting clinical genetic tests, such as the American College of Medical Ge-
netics (ACMG) guidelines [], are deliberately restricted to gene loci with estab-
lished roles in disease. Second, it is notable that many variants purported to be
causal for disease may, in some cases, be benign polymorphisms []. For exam-
ple, we detected  alleles previously reported as pathogenic, but only  actually
appear to explain the phenotype, whereas the remainder were heterozygous or
present in patients with unrelated phenotypes (Supplementary Methods).
We anticipate that the success rate for establishing molecular diagnosis in un-
selected cases of infantile OXPHOS disease using NGS will be higher than that
observed in this study. Indeed, our  patients were refractory to molecular di-
agnosis using traditional methods because most patients had been screened for
common mutations in mtDNA or in relevant genes suggested by phenotype (for
example, POLG and SURF) and were not from informative pedigrees. Analysis
of a representative cohort of  unrelated infantile patients with “deﬁnite” OX-
PHOS disease from theMurdoch Childrens Research Institute, of which  cases

had previous molecular diagnosis, suggests thatMitoExome sequencing could en-
able diagnosis in roughly  of all infantile patients and prioritize candidates in
a further  (see Fig. A. and Supplementary Material).
ree advances will greatly aid interpretation of DNA variation for routine clin-
ical diagnosis. First, NGS studies of Mendelian families will rapidly expand the
set of validated OXPHOS disease–related genes from  to perhaps  nuclear
loci. Second, NGS studies of ethnically diverse, healthy individuals will generate
databases of allele frequencies that are necessary for ﬁltering out common vari-
ants unlikely to cause severe disease, as was recently shown for interpretation
of carrier screening [] and has long been appreciated in the interpretation of
mtDNA variation [, ]. ird, whereas costs currently support MitoExome
sequencing (roughly one-third the cost of exome sequencing), future cost reduc-
tions will enable sequencing of the entire exome or genome, as well as simultane-
ous analysis of parental DNA to detect de novomutations and to conﬁrm themode
of transmission.
e subset of patients for whom a clear molecular etiology was possible spot-
lights the immediate promise of NGS in clinical diagnosis. For these patients, Mi-
toExome sequencing, requiring a single blood or tissue sample, can accelerate clin-
ical diagnosis and enable genetic counseling where appropriate. Genetic diagno-
sis will also enable rational subclassiﬁcation of disease, which may help to predict
clinical course and severity, and lead to patient grouping for targeted therapeutics.
However, we anticipate that evenwith improvements aﬀorded by broader catalogs
of genomic variation, interpretation of most sequence variants will be of greatest
use when integrated with the broader clinical and biochemical presentation.

. M  M
.. P
On the basis of clinical and biochemical criteria from established diagnostic algo-
rithms [], we selected  patients with deﬁnite OXPHOS disease who lacked a
molecular diagnosis (Table .). Of these,  patients were selected from theMur-
doch Childrens Research Institute laboratory and  from the Columbia University
H. Houston Merritt Clinical Research Center. All patients had severe biochemical
OXPHOS defects and were selected to represent ﬁve main categories of OXPHOS
defects: complex I deﬁciency ( patients), complex III deﬁciency ( patients),
complex IV deﬁciency ( patients), combined OXPHOS deﬁciencies ( patients),
and mtDNA depletion ( patients) (Table .). e severity of enzyme defects in
Table . was classiﬁed as marked (<), moderate ( to ), or equivocal
( to ), corresponding to residual activities of normal control mean relative
to citrate synthase or complex II.e inclusion criterionwas infantile age of onset,
deﬁned for this study as under  years of age. e exclusion criterionwasmaternal
family history or presence of a known nuclear or mtDNA mutation. In  cases,
some candidate genes had previously been sequenced and excluded. e study
protocols were approved by the ethics committee at the Royal Children’s Hospital,
Melbourne, Columbia University, and the Massachusetts Institute of Technology.
All samples were obtained as part of diagnostic investigations, and families pro-
vided informed consent.

.. ME  
e . Mb of targeted DNA included the .-kb mtDNA and all coding and un-
translated exons of  nuclear genes, including mitochondrial genes from
theMitoCarta database [],  genes with recent strong evidence of mitochon-
drial association, and  additional genes with weak evidence of mitochondrial
association, all listed in Table S. Gene transcripts from RefSeq [] and Uni-
versity of California Santa Cruz (UCSC) known gene [] collections were down-
loaded from the UCSC genome browser [] assembly hg (February ). All
analyses presented here, except one described in Fig. .A, were restricted to the
mtDNAand coding exons and splice sites of  geneswith conﬁdent evidence of
mitochondrial association (. Mb), because no signiﬁcant results were found in
the untranslated regions (. Mb) or in the coding regions of  auxiliary genes
sequenced (. Mb).
.. H   I 
An in-solution hybridization capture method [] was used to isolate targeted
DNA, which was sequenced on the Illumina GAII platform [] with paired –
base pair (bp) reads. Single -bp baits were synthesized (Agilent) for each tar-
get region or tiled across targets that exceeded  bp. A total of , baits
were synthesized to cover , target regions. Each subject sample was whole
genome–ampliﬁed with a Qiagen REPLI-g Kit with  ng of input DNA. HapMap
and the National Institutes of Mental Health (NIMH) control samples were not
whole genome–ampliﬁed. All samples were sequenced at the Broad Institute Se-
quencing Platform. Genomic DNA was sheared, ligated to Illumina sequencing
adapters, and selected for lengths between  and  bp. is “pond” of DNA

was hybridized with an excess of Agilent baits in solution. e “catch” was pulled
down by magnetic beads coated with streptavidin and then eluted [, ]. Each
patient or HapMap sample was sequenced in one lane of an Illumina GAII instru-
ment. NIMH control samples were subjected to whole-exome hybrid selection
with the same protocol and were sequenced in two or three lanes of an Illumina
GAII instrument with paired -bp reads.
.. S ,  ,  
Illumina reads were aligned to the GRCh reference human genome assembly
with theBWA[] algorithm inSAMtools []within thePicard analysis pipeline
(http://picard.sourceforge.net/). Illumina quality scores were recalibrated and re-
aligned to GRCh, duplicates were removed, and the alignment was modiﬁed to
account for indelswith theGATK software package [] version v... SNVs
were detected and genotyped with the GATK UniﬁedGenotyper in single-sample
mode (with parameters -imALL -mbq -mmq -mm -deletions .). Vari-
ants were ﬁltered with GATK VariantFiltration module (with ﬁlters “QUAL<.
& QD<. & HRun> & DP<” and parameters -cluster  -window ). In-
dels were detected with GATK IndelGenotyperV (with parameters -im ALL) and
ﬁltered with a custom python module that removed sites with a max_cons_av
≥. (maximum average number of mismatches across reads supporting the in-
del) or max_cons_nqs_av_mm ≥. (maximum average mismatch rate in the -
bp NQS window around the indel, across indel-supporting reads). Indels were
genotyped as homozygous (allele balance >.) or heterozygous (allele balance
≤.). Variants were annotated with the GATKGenomicAnnotator with data ob-
tained from RefSeq transcripts [], UCSC known gene transcripts [], known

disease-associated variants obtained from the HGMD [] professional version
., allele frequency fromdbSNP [] version, the GenomesProject
[], and amino acid conservation scores calculated from-vertebrate species align-
ments downloaded from the UCSC genome browser [].
Eight hundred and forty-seven variants likely to be alignment artifacts were
excluded by ﬁltering out variants supported by greater than two Illumina read-
pairs that aligned to the genome in an aberrant orientation. We observed stacks
of aberrantly oriented reads at the boundaries of genomic regions with extremely
high coverage, and sequence mismatches at the boundaries to these regions sug-
gested that the underlying DNA had been circularized before ampliﬁcation and
fragmentation, perhaps during whole-genome ampliﬁcation.
.. DNA  
Analysis of mtDNA variants is challenging given the large copy number of mito-
chondrial genomes per cell, as well as the nuclear genome sequences of mitochon-
drial origin (NUMTs) []. Subject DNA samples typically contain >× copies
of mtDNA molecules compared to nuclear DNA molecules. To avoid alignment
artifacts caused by mtDNA reads being improperly assigned to NUMTs, we sepa-
rately aligned all Illumina reads to the mtDNA revised Cambridge Reference Se-
quence (NC_) using BWA []. Unlike the nuclear genome, read-pairs
with identical alignment positions were retained (resulting in ~,× coverage)
rather than excluded (resulting in ~× coverage) because the observed number
of such duplicate read-pairs matched the expected number based on simulation
of high mtDNA copy number. Variants were detected in each BAM ﬁle with the
GATKUniﬁedGenotyper version v.. in pooled-samplemode to capture het-

eroplasmic variants (with parameters -mbq  -mmq  -mm  -deletions .
-exp -gm POOLED -poolSize  -conﬁdence  -pl SOLEXA). Variants supported
by > of aligned reads were identiﬁed, because it is diﬃcult to resolve low-
heteroplasmy variants from variants present in NUMTs []. mtDNA variants
were annotated with data from MITOMAP [], and allele frequency was ob-
tained from mtDB [].
mtDNA deletions or rearrangements were detected through de novomtDNA as-
sembly with a modiﬁed ALLPATHS assembly approach []. Reads aligned to
the mtDNA were randomly down-sampled to × coverage for computational
tractability. Errors in reads were corrected with the ALLPATHS-LG [] error cor-
rection algorithm. Next, a k-mer graph [] was constructed (k = ) and ﬁltered
using four steps (SupplementaryMethods). Each resultingmtDNA assembly (in a
circular, directed graph representation) was manually inspected to identify alter-
ations supported by> of aligned reads.
.. S, ,  
Sensitivity and speciﬁcity of detectingnuclear SNVs inHapMap individuals (NA,
NA, and NA) were estimated with independent genotype training
data obtained from HapMap Phase  release  [] as well as in Illumina whole-
genome sequence data from the  Genomes Project [] pilot . Genotype con-
cordancewas assessed at  targeted sites that diﬀered betweenHapMapPhase 
and the reference genome, as well as  variant sites based on the Genomes
Project [] pilot . Reproducibility was measured by technical duplicates of sam-
ple NA, fromwhich one aliquot of lymphoblastoid cell line DNAwas used to
create two sequence libraries that were separately hybridized and sequenced, with

genotype concordance observed in  of  sites detected as variant in either
replicate. mtDNA sensitivity and speciﬁcity were calculated at  nonreference
and , reference sites for which independent sequence data were available in
ﬁve patient samples (Newcastle University).
.. V 
Nuclear SNVs and indels that passed quality control metrics were prioritized ac-
cording to three criteria: (i) variants that were rare in healthy individuals, with
SNV allele frequency below . within public databases [dbSNP [] version
and theGenomesProject [] release  including low-passwhole-
genome sequence data from  individuals, and OMNI chip genotype data from
 individuals], consistent with the frequencies observed in  of all  re-
ported pathogenic OXPHOS alleles within HGMD version . []. Because
estimates of indel allele frequency were less robust, only indels absent in the 
Genomes data were considered rare. Variants too common among cases (>
allele frequency) were also excluded. Variants associated with any HGMD disease
phenotype were not excluded, unless associated with allele frequency exceeding
. (ii) Variants predicted to modify protein function, including nonsense, splice
site, coding indel, or missense variants at sites conserved across evolution, as pre-
viously described []. Brieﬂy, eight splice site locations were included (acceptor
sites −, −, −, and donor sites −, , , , ), and missense alleles were required
to be at protein residues that were identical in at least  of  aligned vertebrate
species. (iii) Variants consistent with a recessive model of pathogenesis, includ-
ing homozygous variants or two heterozygous variants present in the same gene.
All rare, protein-modifying, and recessive-type variants in both patient and con-

trol samples were manually reviewed to remove sequence artifacts and to exclude
variants present that were not compound heterozygous based on read or read-pair
evidence.
We prioritized mtDNA variants that were annotated as pathogenic in MITO-
MAP [] and mtDNA deletions or rearrangements that were detected through
de novomtDNA assembly with the ALLPATHS algorithm [].
.. P    
Prevalence of prioritized variants was assessed in patients and in  healthy in-
dividuals of European ancestry obtained with permission from the NIMHControl
Sample collection. Existing whole-exome data for the  controls, generated by
the same Broad Institute Sequencing Platform protocol, were analyzed with the
MitoExome analysis pipeline. Prevalence comparisonswithin the mitochon-
drial geneswere restricted to the  autosomal coding exons thatwerewellmea-
sured in both study designs, totaling  Mb ( of all autosomal coding exons),
where each included exonhad>of bases covered by> sequence reads (base
quality >, mapping quality >), in at least  of patient samples and at least
of control samples. Using the same criteria, we restricted comparisonswithin
the  auxiliary genes to the  autosomal coding exons, totaling  kb (
of all such coding exons), that were well measured in both study designs. Signiﬁ-
cance was assessed by one-sided, unpaired t test with unequal variance (Fig. .A)
and by one-sided Wilcoxon rank sum (Fig. ., B and C). Details of variant preva-
lence in cases and controls are shown in Fig. A.. For patients, we conservatively
excluded heterozygous variants shown to be in cis based on haplotype phasing (
of  cases) as well as variants not validated by Sanger sequencing ( of  vari-

ants). ese exclusionsmay underestimate the degree of enrichment in cases over
controls.
.. V   
All prioritized variants detected inpatientswere independently validated bySanger
sequencing ( of  variants validated), and compound heterozygous variants
were phased through sequencing cDNA (GFM), cloned DNA (BCSL, Corf,
TYMP, MTHFDL), familial DNA (GFM, AGK, EARS), or by a molecular haplo-
typing approach () (ACAD, AARS, POLG) described in Supplementary Meth-
ods. Ten of  putative compound heterozygous variants were conﬁrmed, and
two instances are not yet phased (ACOX and ALDHB). Two heterozygous vari-
ants in MRPL were determined to be on the same maternal haplotype, and
therefore,MRPL was not listed as a prioritized candidate. One Corf vari-
ant was determined to have been introduced by whole-genome ampliﬁcation and
was excluded. e mtDNA deletion was validated by LR-PCR with primers F
(m._) and DR (m._) and Sanger sequencing with internal primers
near the breakpoint (available on request). eheteroplasmy level in skeletalmus-
clewas determinedby quantitative real-timePCRas previously described [], and
the relative abundance of mtDNA versus nuclear DNA was measured in patient
and control tissues as previously described [].
.. E  
Multiple assayswere performed to support thepathogenicity of novel alleleswithin
genes known to cause OXPHOS disease (Fig. A.-A.). Presence and segregation
of alleles in family members (when available) were assayed by Sanger sequencing.

e eﬀect of mutations on mature RNA transcript splicing and abundance was
measured in patient and control ﬁbroblasts by reverse transcription–PCR (RT-
PCR) in the presence and absence of cycloheximide ( ng/µl) for  hours to
inhibit nonsense-mediated decay []. Relative abundance of full-length pro-
tein products and OXPHOS subunits or assembly factors from all ﬁve complexes
was measured in patient and control ﬁbroblast lines and skeletal muscle via SDS–
polyacrylamide gel electrophoresis (SDS-PAGE) Western blot[, ]. Prioritized
genes were excluded if they did not segregate with disease in the family (FAMA
in P andCOX in P) or if variants showed>. allele frequency in healthy
individuals (MUL in P andMRPL in P). See SupplementaryMethods for de-
tails. Prioritized variants were within individuals of western European ancestry,
except as noted below, and therefore, allele frequencies were obtained from the
GenomesProject (Table S). Prioritized variantswithin patients of Lebanese
decent (P, P, P, P, P, P, P, P, and P) were screened with
Sequenom in  ethnically matched chromosomes. Only the ACADSB variant
(homozygous in P) was present in any other sample, where it was observed in
heterozygous state in  of  Lebanese chromosomes (. allele frequency).
Ethnically matched allele frequencies were not obtained for prioritized variants
in P (Vietnamese ancestry), P (Pakistani ancestry), P, or P (uncertain
ancestry).
.. M 
Molecular karyotyping of proband P and maternal DNA samples was performed
with the Illumina HumanCytoSNP- array (version .) as previously described
[]. Automated LCSH detection was performed with the CNVPartition v..

algorithm in KaryoStudio software. SNP genotypes were generated in GenomeS-
tudio software (Illumina) with data from a set of  intra-run samples. Both the
proband and the maternal DNA samples yielded an SNP call rate of .. Iden-
tity by state (IBS) analysis, assessing the sharing of alleles between individuals,
was performed with the online SNPduo program [] (http://pevsnerlab.
kennedykrieger.org/SNPduo) with default parameters.
.. NDUFB 
e NDUFB open reading frame (ORF) was ampliﬁed from control ﬁbroblast
cDNA and cloned into the -hydroxytamoxifen–inducible lentiviral vector pF-
xUAS-MCS-SV-puroGalERTVP (GEV)-W [] with 0 Bci I and 0 Xba
I. e pF-xUAS-Corf-SV puroGEV-W vector was described previously
[]. To generate lentiviral particles, we grew human embryonic kidney (HEK)
T cells on -cm plates to  conﬂuence and cotransfected them using Ef-
fectene reagents (Qiagen) with packaging plasmid (pCMVR.), a pseudotyping
plasmid (pCMV-VSVg), and either pF-xUAS-NDUFB-SV puroGEV-W or
pF-xUAS-Corf-SV puroGEV-W. Fresh medium was applied to the cells
 hours after transfection, and after another  hours of incubation, super-
natants containing packaged virus were harvested and ﬁltered through a .-
µm membrane ﬁlter. Primary human ﬁbroblasts were infected with viral super-
natant along with polybrene ( µg/ml) (Sigma) for  hours. Cells were grown
in antibiotic-free medium for  hours before application of selection medium
containing puromycin ( µg/ml). We found that our lentivectors were “leaky”
in primary human ﬁbroblast lines and that suﬃcient expression of Corf and
NDUFB was achieved without tamoxifen induction. After  days of selection,

cells were harvested for enzyme activity assays and SDS-PAGE Western blotting.
.. C I  IV   
Complex I and complex IV dipstick activity assays (MitoSciences) were performed
on  and  µg, respectively, of cleared cell lysates according to the manufac-
turer’s protocol. AHamamatsu ICA- immunochromatographic dipstick reader
wasused for densitometry. Two-way repeated-measures analysis of variance (ANOVA)
was used for comparisons of groups followed by post hoc analysis with Bonferroni
method to determine statistically signiﬁcant diﬀerences.
. M I
.. P P A
A previous version of this chapter appeared in []:
Sarah E Calvo, AlisonG Compton, StevenGHershman, Sze Chern Lim, Daniel S
Lieber, Elena JTucker, AdrienneLaskowski, CaterinaGarone, ShangtaoLiu,DavidB
Jaﬀe, John Christodoulou, Janice M Fletcher, Damien L Bruno, Jack Goldblatt,
Salvatore DiMauro, David R orburn, and Vamsi K Mootha. Molecular Diagno-
sis of Infantile Mitochondrial Disease with Targeted Next-Generation Sequencing
. Science Translational Medicine, ():ra–ra, January . URL
http://stm.sciencemag.org/content///ra.abstract
.. A’ C
is study was conceived and designed by S.E.C., D.R.T., S.D., and V.K.M. Char-
acterization of patient phenotypes was performed by J.C., J.M.F., and J.G. Next-
generation sequencing analysis was performed by S.G.H., D.S.L., and S.E.C., with

mtDNA assembly performed by D.B.J. Variant validation and follow-up on patient
sampleswere performed byA.G.C., S.C.L., S.L., C.G., E.J.T., D.L.B., andA.L.Molec-
ular haplotyping was performed by S.G.H. e manuscript was written by S.E.C.,
A.G.C., S.G.H., S.C.L., S.D., D.R.T., and V.K.M. All aspects of the study were super-
vised by D.R.T. and V.K.M.
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Mutations inMTFMT Underlie a Human
Disorder of Formylation Causing Impaired
Mitochondrial Translation
T   translation machinery is unusual in havinga single tRNAMet that fulﬁlls the dual role of the initiator and elongator
tRNAMet. A portionof theMet-tRNAMet pool is formylated bymitochondrialmethionyl-
tRNA formyltransferase (MTFMT) to generateN-formylmethionine-tRNAMet (fMet-

tRNAMet), which is used for translation initiation; however, the requirement of
formylation for initiation in human mitochondria is still under debate. Using
targeted sequencing of the mtDNA and nuclear exons encoding the mitochon-
drial proteome (MitoExome), we identiﬁed compound heterozygous mutations in
MTFMT in two unrelated children presenting with Leigh syndrome and combined
OXPHOS deﬁciency. Patient ﬁbroblasts exhibit severe defects in mitochondrial
translation that can be rescued by exogenous expression ofMTFMT. Furthermore,
patient ﬁbroblasts have dramatically reduced fMet-tRNAMet levels and an abnor-
mal formylation proﬁle ofmitochondrially translated COX. Our ﬁndings demon-
strate that MTFMT is critical for eﬃcient human mitochondrial translation and
reveal a human disorder of Met-tRNAMet formylation.
. I
Of the ~ protein components of the oxidative phosphorylation (OXPHOS) ma-
chinery,  are encodedby themitochondrialDNA (mtDNA) and translatedwithin
the organelle. Defects in mitochondrial protein synthesis lead to combined OX-
PHOSdeﬁciency. Although themtDNA encodes the ribosomal and transfer RNAs,
all remaining components of the mitochondrial translational machinery are en-
coded by nuclear genes and imported into the organelle. To date, mutations in
more than  diﬀerent nuclear genes have been shown to cause defective mito-
chondrial translation in humans. However, molecular diagnosis by sequencing
these candidates in patients with defects in mitochondrial translation is far from
perfect [], underscoring the need to identify additional pathogenic mutations
underlying these disorders.
Translationwithinmetazoanmitochondria is reminiscent of the bacterial path-

way, initiating with N-formylmethionine (fMet) []. Unlike bacteria, which en-
code distinct tRNAMet molecules for translation initiation and elongation, meta-
zoan mitochondria express a single tRNAMet that fulﬁlls both roles []. After
aminoacylation of tRNAMet, a portion ofMet-tRNAMet is formylated bymitochon-
drialmethionyl-tRNA formyltransferase (MTFMT) to generate fMet-tRNAMet. e
mitochondrial translation initiation factor (IFmt) has high aﬃnity for fMet-tRNAMet,
which is recruited to the ribosomal P-site to initiate translation []. In contrast,
the mitochondrial elongation factor (EF-Tumt) speciﬁcally recruits Met-tRNAMet
to the ribosomal A-site to participate in polypeptide elongation. Synthesized pro-
teins can then be deformylated by amitochondrial peptide deformylase (PDF) and
demethionylated by a mitochondrial methionyl aminopeptidase (MAPD)[,
].
Here, we applied targeted exome sequencing to two unrelated patients with
Leigh syndrome and combined OXPHOS deﬁciency to discover pathogenic mu-
tations in MTFMT. Fibroblasts from these patients have impaired Met-tRNAMet
formylation, peptide formylation, and mitochondrial translation. Despite stud-
ies in yeast suggesting thatMTFMT is not essential for mitochondrial translation
[, , ], we show that in humans this gene is required for eﬃcient mito-
chondrial translation and function.
. R
.. M       -
  L 
We studied two unrelated patients with Leigh syndrome and combined OXPHOS
deﬁciency (Fig. .A). Clinical summaries for Patient  (P) and Patient  (P)

are provided in Supplementary Data. Patient ﬁbroblasts had reduced synthesis
of most mtDNA-encoded proteins as assayed by [³⁵S]-methionine labeling in the
presence of inhibitors of cytosolic translation (Fig. .B). is correlated with re-
duced steady state protein levels as detected by immunoblotting (Fig. .C), and,
at least for ND, was not due to reduced mRNA (Fig. B.). Collectively, these data
suggest a defect in translation of mtDNA-encoded proteins.
.. ME S IMTFMT M
Toelucidate themolecular basis of disease inP andP, weperformednext-generation
sequencing of coding exons from  nuclear-encodedmitochondrial-associated
genes and the mtDNA (collectively termed the “MitoExome”). DNA was captured
via an in-solution hybridization method [] and sequenced on an Illumina GA-II
platform []. Details are provided in the Supplemental Results and Table ..
Table 3.1: Next-generation sequencing statistics. Q20 = Phred-scaled quality
￿20, nuDNA = MitoExome nuclear DNA, Cov = coverage
P P
Bases Targeted ,,
Q Bases ,, ,,,
 selected  
nuDNA Cov (X)  
mtDNA Cov (X) , 
Bases Analyzed ,,
Cov >=  ,, (.) ,, (.)
<Cov< , (.) , (.)
Uncovered , (.) , (.)
Diﬃcult to align , (.) , (.)
We identiﬁed ~ single-nucleotide variants (SNVs) and short insertion or
deletion variants (indels) in each patient relative to the reference genome, and pri-

Figure 3.1: Combined OXPHOS deﬁciency due to a defect in mitochon-
drial translation. (A) Biochemical analysis of OXPHOS complexes relative to cit-
rate synthase (CS) in ﬁbroblasts (Fb), muscle (M) or liver (L), expressed as a %
of mean from healthy controls. (B) SDS-PAGE analysis of 35S-methionine-labeled
mtDNA-encoded proteins from control and patient ﬁbroblasts. MtDNA-encoded sub-
units of complex I (ND1, ND2, ND3, ND5, ND4L), complex III (cytb), complex IV
(COX1, COX2, COX3) and complex V (ATP6, ATP8) are shown. (C) Gel in (b) was
immunoblotted with antibodies against mtDNA-encoded ND1, COX1, COX2 and
nuclear-encoded SDHA (complex II; loading control). See also Fig. B.1.

oritized those that may underlie a severe, recessive disease (Fig. .A). We ﬁrst ﬁl-
tered out likely benign variants present at a frequency of >. inpublic databases
which left ~ variants in each patient. We thenprioritized variants thatwere pre-
dicted to have a deleterious impact on protein function [], leaving ~ variants.
Focusing on genes that ﬁt autosomal recessive inheritance, having either homozy-
gous variants or two diﬀerent variants in the same gene, only one candidate gene,
MTFMT, remained in each patient (Fig. .A).

Fi
gu
re
3.
2:
Id
en
tiﬁ
ca
tio
n
of
Co
m
po
un
d
He
te
ro
zy
go
us
M
ut
at
io
ns
in
M
TF
M
T.
(A
)N
um
be
ro
fM
ito
Ex
om
ev
ari
an
ts
th
at
pa
ss
pr
ior
iti
za
tio
n
ﬁlt
ers
.(
B)
Sc
he
ma
tic
dia
gr
am
of
M
TF
M
T
sh
ow
ing
th
el
oc
at
ion
of
mu
ta
tio
ns
in
P1
an
d
P2
(re
d
ba
rs)
,e
xo
n
sk
ip-
pin
g
(g
ray
bo
xe
s),
an
d
pr
im
ers
for
RT
-P
CR
(fo
rw
ard
an
d
rev
ers
ea
rro
ws
).
(C
)E
lec
tro
ph
or
es
is
of
RT
-P
CR
pr
od
uc
ts
de
mo
ns
tra
tes
a
sm
all
er
cD
NA
sp
ec
ies
(2
80
bp
)i
n
P1
an
d
P2
th
at
is
pa
rti
cu
lar
ly
pr
om
ine
nt
in
ce
lls
gr
ow
n
in
th
ep
res
en
ce
of
cy
clo
he
xim
ide
(+
CH
X)
.
To
p:
Se
qu
en
ce
ch
ro
ma
to
gr
am
so
ff
ull
-le
ng
th
M
TF
M
T
RT
-P
CR
pr
od
uc
ts
(–
CH
X)
to
co
nﬁ
rm
co
mp
ou
nd
he
ter
oz
yg
os
ity
.B
ot
to
m:
Se
qu
en
ce
ch
ro
ma
to
gr
am
so
ft
he
sm
all
er
RT
-P
CR
pr
od
uc
ts
(+
CH
X)
sh
ow
sp
at
ien
tc
DN
A
lac
ks
th
ec
.38
2C
!
T
(P
1)
or
c.3
74
C!
T
(P
2)
mu
ta
tio
ns
an
d
sk
ips
ex
on
4,
wh
ich
ca
rri
es
th
es
ha
red
c.6
26
C!
T
mu
ta
tio
n.
Se
ea
lso
Fi
g.
B.
2
an
d
Ta
ble
3.1
.

We identiﬁed three distinct heterozygous variants in our patients (Fig. .B).
Both patients harbor a c.C!Tmutation. e c.C site is  bp upstream of
the ￿ end of exon  and is predicted to eliminate two overlapping exonic splic-
ing enhancers (GTCAAG, TCAAGA) [] and to generate an exonic splicing sup-
pressor (GTTGTT) []. Skipping of exon  results in a frameshift and prema-
ture stop codon (p.RSfsX). e second mutation in P is a nonsense mu-
tation (c.C!T, p.RX), while the second mutation in P changes a highly
conserved serine to leucine in the catalytic core of MTFMT (c.C!T, p.SL)
(Fig. B.). An aﬀected cousin of P also carries the c.C!T and c.C!Tmu-
tations.
As predicted by in silico analysis, the shared c.C!T mutation caused skip-
ping of exon  (Fig. .C). qRT-PCR analysis revealed that P had only  full-
length MTFMT transcript compared to controls (Fig. B.), the majority of which
carries the c.C!T nonsense mutation and lacks the c.C!T splicing muta-
tion (Fig. .C). P had  full-lengthMTFMT transcript (Fig. B.), all of which
appears to carry the c.C!T mutation and to lack the c.C!T splicing mu-
tation (Fig. .C). Collectively, these results conﬁrm compound heterozygosity of
theMTFMT mutations and almost complete exon skipping due to the c.C!T
mutation.
.. M T I R  P F
 E MTFMT
Weused complementaryDNA (cDNA) complementation to prove that the transla-
tion defect in these patients is due tomutations inMTFMT. Fibroblasts from both
patients showed reduced levels of themtDNA-encoded complex IV subunit, COX,

consistent with a defect in mitochondrial translation, and of the nuclear-encoded
complex I subunit, NDUFB, reﬂecting instability of complex I in the absence of
mtDNA-encoded proteins (Fig. .A). Lentiviral transduction of MTFMT cDNA
caused a signiﬁcant increase of COX and NDUFB in both patients (Fig. .B).
In contrast, lentiviral transduction of a control cDNA, Corf, caused no change
of these subunits (Fig. .B).ese data conﬁrm that anMTFMT defect is respon-
sible for the combined OXPHOS deﬁciency in these patients.
.. M RNAM P A A  P F-

To directly analyze the mitochondrial tRNAMet pools (Fig. .A), we used a modi-
ﬁedprotocol of acid-ureaPAGE followedbynorthernblotting [, , ] (Fig. .B).
We were able to separate the mitochondrial uncharged tRNAMet, Met-tRNAMet,
and fMet-tRNAMet from total RNA isolated from ﬁbroblasts and to show that two
independentwild-type cell lines containeduncharged tRNAMet and fMet-tRNAMet,
but very little Met-tRNAMet (Fig. .B, lanes –). In striking contrast, ﬁbrob-
lasts from P and P lacked detectable fMet-tRNAMet and contained mostly Met-
tRNAMet along with traces of the uncharged tRNAMet (Fig. .B, compare lanes
– to control lanes –). We also observed a .-fold increase of the overall mi-
tochondrial tRNAMet signal in patient ﬁbroblasts compared to control (Fig. .B,
top panel; compare lanes  and  to control lane ), while the cytoplasmic initia-
tor tRNAiMet showed constant signal throughout (Fig. .B, bottom panel). e
analysis of the mitochondrial tRNAMet pools clearly shows a defect in tRNAMet
formylation.

Figure 3.3: Proving pathogenicity of MTFMT. Patient and control ﬁbroblasts
were transduced with MTFMT cDNA or control C8orf38 cDNA. (A) Representative
SDS-PAGE western blot shows reduced COX2 and NDUFB8 in patient ﬁbroblasts and
restoration of protein levels with MTFMT but not C8orf38 transduction. The 70kDa
complex II subunit acts as a loading control.(B) Protein expression was quantiﬁed
by densitometry and bar charts show the level of complex I (NDUFB8) or complex
IV (COX2) relative to complex II (70 kDa) normalized to control, before and after
transduction. Error bars show the mean of three biological replicates and error bars
indicate ± 1 standard error of the mean (SEM). Asterisks indicate p < 0.05 (*), p <
0.01 (**), and p < 0.001 (***).

Figure 3.4: Patient Fibroblasts Have a Defect in Met-tRNAMet Formylation.
(A) In metazoan mitochondria, a single tRNAMet species acts as both initiator and
elongator tRNAMet. After aminoacylation of tRNAMet by the mitochondrial methionyl-
tRNA synthetase (MetRSmt), a portion of Met-tRNAMet is formylated by MTFMT to
generate fMet-tRNAMet. fMet-tRNAMet is used by the mitochondrial IF2 (IF2mt) to
initiate translation, whereas Met-tRNAMet is recognized by the mitochondrial EF-Tu
(EF-Tumt) for the elongation of translation products. (B) Total RNA from control
(lanes 5–7) and patient ﬁbroblasts (P1, lanes 8–10; P2, lanes 11–13) was separated
by acid-urea PAGE. Total RNA from MCH58 cells is shown as a reference (lanes 1–
4). The mitochondrial tRNAMet (top) and the cytoplasmic initiator tRNAiMet (bot-
tom) were detected by northern hybridization. Total RNA was isolated under acidic
conditions, which preserves both the Met-tRNAMet and fMet-tRNAMet (ac); tRNAs
were treated with copper sulfate (Cu+), which speciﬁcally deacylates Met-tRNAMet
but not fMet-tRNAMet, or with base (OH−), which deacylates both Met-tRNAMet
and fMet-tRNAMet. Base-treated tRNA was reaminoacylated in vitro with Met using
MetRS generating a Met-tRNAMet standard (M).

.. COX P F I D  P F
Although ﬁbroblasts from P and P have severely impaired mitochondrial trans-
lation, they do retain residual activity (Fig. .B). is residual activity could be
due to () low activity of mutant MTFMT generating a small amount of fMet-
tRNAMet that is rapidly consumed in translation initiation and, therefore, unde-
tectable by Northern blot analyses and/or () the human IFmt recognizing, albeit
weakly, the nonformylatedMet-tRNAMet species to support translation initiation.
Translation through the ﬁrstmechanismwould produce formylated protein, while
translation through the second mechanism would produce unformylated protein.
To investigate these two possibilities, we used semiquantitative mass spectro-
metric analysis to simultaneously measure three possible N-terminal states of mi-
tochondrially translated COX: formylated (Fig. .A), unformylated (Fig. .B),
and demethionylated (des-Met) (Fig. .C).We applied thismethod to complex IV
immunoprecipitated from ﬁbroblasts from P and P and two independent wild-
type cell lines (Fig. .D). Although no fMet-tRNAMet was detected in patient ﬁ-
broblasts by northern blotting (Fig. .B), the dominant COX peptide in all four
samples is the formylated species as estimated from total ion current of each form
(Fig. .E). e expression of mitochondrial PDF and MAPD was normal in pa-
tient ﬁbroblasts (Fig. B.). ese semiquantitative analyses clearly demonstrate
that patient ﬁbroblasts retain residual MTFMT activity.
. D
Here, we report human patients with mutations in MTFMT, a gene that has not
been previously linked to human disease. We veriﬁed the causal mutations by
rescuing the mitochondrial translation defects in patient ﬁbroblasts via lentiviral

Figure 3.5: Analysis of the COX1 N-terminus in Patient Fibroblasts. (A–C)
Annotated MS/MS spectra conﬁrming correct targeting of the three possible N-
termini of COX1. The sequence of the peptide is MFADRWLFSTNHK where the
Met residue may be (A) formylated, (B) unformylated, or (C) absent (des-Met). In-
sets show high-resolution, high-mass accuracy precursors from which the fragmenta-
tion spectra were derived. Given their sequence similarity, peptides are expected to
have similar ionization eﬃciencies. (D) Extracted ion chromatograms (XICs) of three
N-terminal states of COX1 ([fMet,Met,des-Met]FADRWLFSTNHK), normalized to
an internal COX1 peptide (VFSWLATLHGSNMK). (E) Fractional ion current of the
three N-terminal states of COX1 from immunoprecipitated complex IV of patients and
controls. See also Fig. B.3.

transduction of MTFMT. Analysis of the tRNAMet pools in patient ﬁbroblasts re-
vealed severe MTFMT dysfunction. To our knowledge, the human mitochondrial
tRNAMet proﬁle has not been previously reported. It is interesting to note that
control ﬁbroblasts lack detectable Met-tRNAMet, suggesting that it is utilized as
quickly as it is produced; either converted to fMet-tRNAMet or used to donateMet
to the growing polypeptide chain. Strikingly, patient ﬁbroblasts lack detectable
levels of fMet-tRNAMet and contain mostly Met-tRNAMet.
Drastically decreased fMet-tRNAMet levels prevent eﬃcientmitochondrial trans-
lation as demonstrated by the reduced translation observed in patient ﬁbroblasts.
Although ﬁbroblasts from P and P have severely impaired mitochondrial trans-
lation, they do retain some residual activity. To understand the origin of this ac-
tivity, we measured the relative distribution of three possible N-terminal states
of mitochondrially translated COX by mass spectrometry. While previous stud-
ies have interrogated the formylation status of the N-terminus of COX [], our
study interrogates all three modiﬁcation states and demonstrates mitochondrial
methionine excision activity, which is detectable albeit weak.
FormylatedCOX is thedominant species in patientﬁbroblasts, indicating resid-
ual MTFMT activity. Assuming P’s nonsensemutation has a full loss of function,
then the allele harboring the shared c.C!Tmutationmust conferMTFMT ac-
tivity. Transcript that has not undergone skipping of exon  encodes an MTFMT
variant harboring a p.SL missense mutation. Residue p.S is moderately
conserved and lies on the periphery ofMTFMTbased on homologywith the bacte-
rial enzyme. Similarly, P’s residual MTFMT activity must originate from enzyme
variants carrying the p.SL mutation and/or the p.SL mutation located in
the active site.

Studies in bacteria and yeast have raised questions about the absolute require-
ment for Met-tRNAMet formylation. Formylation is not essential in all bacteria
[] and in yeast disruption of FMT causes no discernible defect in mitochon-
drial protein synthesis or function [, , ]. Additionally, bovine IFmt is
able to restore respiration in a yeast mutant lacking both IFmt and FMT [],
suggesting that bovine IFmt, like yeast IFmt, can initiate protein synthesis with-
out fMet-tRNAMet. However, a number of studies inmammals indicate that formy-
lation ofmitochondrialMet-tRNAMet is required for translation initiation. Bovine
IFmt has a - to -fold greater aﬃnity for fMet-tRNAMet than forMet-tRNAMet
in vitro [] and  of the  bovinemtDNA-encoded proteins retain fMet at the
N-terminus [].
What are the factors that could allow nonformylated Met-tRNAMet to initiate
mitochondrial translation? In Salmonella typhimurium, ampliﬁcation of initiator
tRNA genes compensates for a lack of methionyl-tRNA formyltransferase activity
and allows translation initiation without formylation of the initiator tRNA [].
e “upregulation” of themitochondrial tRNAMet in patient ﬁbroblasts (Fig. .B)
could, in principle, be a compensatory response due to limited fMet-tRNAMet.
In summary, we have usedMitoExome sequencing to identifyMTFMT as a gene
underpinning combinedOXPHOS deﬁciency associated with Leigh syndrome. We
have shown that patient ﬁbroblasts have a striking deﬁciency of fMet-tRNAMet
leading to impaired mitochondrial translation. Despite studies in yeast suggest-
ing thatMTFMT is not essential formitochondrial translation [, , ], we
show here that in humans this gene is required for eﬃcient mitochondrial trans-
lation and function. More generally, this study demonstrates how MitoExome
sequencing can reveal insights into basic biochemistry and the molecular basis of

mitochondrial disease.
. E P
.. C C
Cells were grown at  C and  CO in Dulbecco’s modiﬁed Eagle’s medium
(DMEM; Invitrogen, Carlsbad, CA) supplementedwith (v/v) fetal bovine serum
(FBS, Invitrogen).
.. B A
Spectrophotometric analysis of mitochondrial OXPHOS activity was performed
as described previously (Kirby et al., ). Investigations were performed with
informed consent and in compliance with ethics approval by the Human Research
Ethics Committee of the Royal Children’s Hospital, Melbourne.
.. T A
MtDNA-encodedproteins in patientﬁbroblastswere labeledwith ³⁵S-methionine/³⁵S-
cysteine (EXPRE³⁵S³⁵S Protein Labeling Mix; Perkin Elmer Life Sciences) prior to
mitochondrial isolation and analysis of translation products by SDS-PAGE as pre-
viously described [].
.. SDS-PAGE  I
Immunoblotting was performed as previously described []. Proteins were de-
tected with the following antibodies: complex II - kDa subunit monoclonal
antibody (MitoSciences, MS), ND polyclonal antibody (kind gift from Anne
Lombes, Paris),-complex IV subunit Imonoclonal antibody (Invitrogen, ),

-complex IV subunit IImonoclonal antibody (Invitrogen, A), TotalOXPHOS
Human WB Antibody Cocktail containing NDUFB and COX (MitoSciences,
MS), and either -mouse or -rabbit IgG horseradish peroxidase (HRP; Dako-
Cytomation).
.. ME S
We used an in-solution hybridization capture method [] to isolate target DNA,
which was sequenced on the Illumina GA-II platform []. e .Mb of targeted
DNA included the  kb mtDNA and all coding and untranslated exons of 
nuclear genes, including  mitochondrial genes from the MitoCarta database
[],  genes with recent strong evidence ofmitochondrial association, and 
additional genes. All analyses were restricted to the mtDNA and coding exons of
the  genes with conﬁdent evidence of mitochondrial association (. Mb).
Detailed methods for target selection, sequencing, alignment and variant detec-
tion are in Chapter .
.. V P
Diﬀerences inDNA sequence between each individual and theGRChhuman ref-
erence assembly were identiﬁed. Nuclear variants that passed quality controlmet-
rics were prioritized according to three criteria: () SNV allele frequency <.
in public databases (dbSNP [] version  and the  genomes project []
released November ) or indels absent in the  genomes data, () variants
predicted to modify protein function as previously described [], and () vari-
ants consistent with recessive inheritance (homozygous variants or two heterozy-
gous variants in the same gene). We also prioritized mtDNA variants annotated

as pathogenic in MITOMAP []. Detailed methods are in Chapter .
.. S DNA S
DNA isolation, RNA isolation, cDNA synthesis, inhibition of nonsense mediated
decay, and sequencing of PCR products were performed as described previously
[].
.. L T
e MTFMT open reading frame (ORF) was purchased in a pCMV-
SPORT vector (Clone ID: BC., Open Biosystems) and
was cloned into the -hydroxytamoxifen-inducible lentiviral vector,
pF_x_UAS_MCS_SV_puroGEV-W []. MTFMT viral particles were
generated and patient ﬁbroblasts were transduced as described previously [].
ree independent transductions were performed and cells were harvested after
– days selection with  µg/ml puromycin.
.. A-U PAGE  N B
Total RNA was isolated from frozen cells under acidic conditions with TRIzol (In-
vitrogen) according to the manufacturer’s instructions. Acid-washed glass beads
(. mm diameter; Sigma) were added during extraction. Total RNAs were sepa-
rated by acid-urea PAGE as described previously [, , ]withmodiﬁcations.
In brief, . A units of each RNA sample were loaded onto a . polyacry-
lamide gel containing  M urea and . M sodium acetate (pH .). Individual
tRNAs were detected by northern blotting [] with the following hybridization
probes: 0TAGTACGGGAAGGGTATAA0 (mitochondrial tRNAMet) and0TTCCACTGCACCACTCTGCT0

(cytoplasmic initiator tRNAiMet). Northern blots were quantiﬁed by Phospho-
rImager analysis with ImageQuant software (Molecular Dynamics). Experiments
were performed induplicate. Aminoacyl-tRNAs and formylaminoacyl-tRNAswere
deacylated by base treatment in . M Tris-HCl (pH .) at  C for  min, fol-
lowed by incubation at  C for  hr. Aminoacyl-tRNAs were selectively deacy-
lated by treatment with copper sulfate as described []. Total RNAwas aminoa-
cylated in vitro with methionine using E. coliMetRS as previously described with
minor modiﬁcations [].
.. M S A  COX N-
In brief, complex IV was immunoprecipitated from control and patient ﬁbroblasts
withMitoSciences’ complex IV Immunocapture kit (MS-) and separated by gel
electrophoresis on a NuPAGE – Bis-Tris gel (Invitrogen). A band corre-
sponding to the MW of COX was excised and subjected to in-gel Lys-C digestion
(Kinter and Sherman). Extracted peptides were separated on C column with a
-Series nano-LC pump (Agilent) and run on a LTQ-Velos-Orbitrapmass spec-
trometer (ermoFisher) set to scan and to targetedMS/MS form/zs correspond-
ing to the z =  states of the unformylated, formylated and des-Met species of the
N-terminal peptide of COX (MFADRWLFSTNHK).
Extracted ion chromatographs (XICs) were generated from the Orbitrap sur-
vey scans based on the z =  states of the unformylated, formylated and des-Met
species of theN-terminal peptide of COXusing XCalibur software (ermoFisher
Scientiﬁc). e identities of the peaks corresponding to these species were veri-
ﬁed with the accompanying static MS/MS spectra (Figs. .A-C). e areas under
these peaks were integrated with the Genesis peak detection algorithm included

in XCalibur with all standard defaults. Peak areas were further normalized to the
peak area of a distal peptide of COX (VFSWLATLHGSNMK,m/z ., z = )
to ensure that comparisons allowed for the diﬀerent amounts of COX in control
and patient samples. Full methods are in the Appendix B.
.. S A
Two-way repeated-measures analysis of variance (ANOVA) was used for compar-
isons of groups followed by post hoc analysis via the Bonferroni method.
.. A N
e GenBank accession number for the MTFMT sequence reported in this paper
is NM_..
. M I
.. P P A
A previous version of this chapter appeared in []:
Elena J. Tucker, StevenG.Hershman, CarolineKöhrer, CaseyA. Belcher-Timme,
Jinal Patel, Olga A. Goldberger, John Christodoulou, Jonathon M. Silberstein,
MatthewMcKenzie,Michael T. Ryan, AlisonG. Compton, JacobD. Jaﬀe, StevenA.
Carr, Sarah E. Calvo, Uttam L. RajBhandary, David R. orburn, and Vamsi K.
Mootha. Mutations in MTFMT Underlie a Human Disorder of Formylation Caus-
ing ImpairedMitochondrial Translation, September . URLhttp://linkinghub.
elsevier.com/retrieve/pii/S

.. A’ C
is study was conceived and designed by D.R.T. and V.K.M. Characterization of
patient phenotypes was performed by J.C. and J.S. Biochemical analysis was per-
formed by E.J.T., A.G.C., M.M., and M.T.R. Next-generation sequencing analysis
was performed by S.G.H and S.E.C. Variant validationwas performed by E.J.T. and
A.G.C. cDNA rescue was performed by E.J.T. and O.A.G. Northern blots were per-
formed by C.K. and C.A.B. Mass Spectrometry was performed by J.P., J.D.J, S.A.C.
and C.A.B.emanuscript was written by E.J.T., S.G.H., C.K., J.D.J, U.L.R., D.R.T.
and V.K.M. All aspects of the study were supervised by U.L.R., D.R.T. and V.K.M.

What’s cool is that we’re a mosaic of pieces of genomes...None
of us is truly normal.
Evan Eichler, []
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Copy Number Variant Detection From
Targeted Sequencing Data
S , such as large ampliﬁcations anddeletions, are knownto contribute to human disease but are rarely detected in targeted sequenc-
ing experiments. In this chapter, we evaluate the ability to detect copy number
variants (CNVs) from the read depths of whole-exome sequencing data and evalu-
ate the utility of including CNVs when analyzing theMitoExomes of patients with
suspected mitochondrial disease. We expand upon a previously published CNV

detection algorithm, CoNIFER, which uses singular value decomposition (SVD) to
isolate and remove noise in the read depths of targeted sequencing experiments
in order to facilitate the detection of rare CNVs. In exome data from a control
set of individuals that had previously undergone CNV detection via genome-wide
array-CGH, we are able to recover  of deletions and  of ampliﬁcations.
Performance is better when recovering synthetically inserted variants; however,
events that overlap few, highly variable and/or poorly covered targets are diﬃ-
cult to detect. To facilitate the evaluation of CNV callsets in a cohort of  pa-
tients with suspected mitochondrial disease, we developed a web-interface, CN-
Visualizer, which integrates CNV calling with other genetic and phenotypic infor-
mation. In one patient, we detect an event consistent with the kb common
deletion responsible for ~ of cases of Krabbe Disease. In another, we detect
an ampliﬁcation of chromosome p!pter that is consistent with the patient’s
multi-systemic disorder. We ﬁnd signals for deletions in genes that already had a
prioritized variant and were consistent with phenotypic information in four pa-
tients. ree of these deletions have signal from single exons and need to be con-
ﬁrmed. In two patients with Leigh syndrome and the pathogenic p.SL variant
described in Chapter , we detect exons with low coverage in the mitochondrial
methionyl-tRNA formyltransferase (MTFMT). In a patient who ﬁrst presented af-
ter a teenage bout of ﬂu with a series of symptoms consistent with adult Refsum
disease, we detect a deletion in the promoter region of phytanoyl-CoA hydroxy-
lase (PHYH) that may be compound heterozygous with a known partial loss-of-
function variant. Progression of symptoms in Refsum disease can be avoided by
reducing dietary intake of phytanic acid, a fatty acid whose catabolism requires
PHYH activity. Lastly, in a  year-old male patient with cerebellar ataxia, pe-

ripheral neuropathy, azoospermia, andmild hearing losswe detect, conﬁrmed and
phased a kb heterozygous deletion that was compounded with a likely loss-of-
functionmissense variant in D-bifunctional protein, HSDB, a peroxisomal en-
zyme that catalyzesmultiple steps of beta-oxidation of very long chain fatty acids.
Retrospective review of metabolic testing from this patient revealed alterations
of long- and very-long chain fatty acid metabolism consistent with a peroxisomal
disorder. ese vignettes illuminate the capabilities and limitations of CNV de-
tection from targeted sequencing data and demonstrates the importance of CNV
detection for clinical diagnostics.
. I
To date, we have sequenced the MitoExome of over  cases and controls. We
evaluated single nucleotide polymorphisms (SNPs) and short insertion and dele-
tions (indels) to prioritize genes with rare, proteinmodifying variants that ﬁt a re-
cessivemodeof inheritance andmatched thepatient phenotype. In one case, a sin-
gle rare protein modifying variant in POLG was prioritized, as that gene had pre-
viously been shown to act dominantly. We benchmarked MitoExome sequencing
performance on two cohorts of individuals:  infants with severe mitochondrial
disease (Chapter ) and  patients with suspected mitochondrial disease[].
While many samples had at least one candidate disease gene, a striking number
lack convincing candidates (Fig. .).
ere are a number of reasons why a genetic test may not be fully informative
(Fig. .). e cause of disease in some cases may not be genetic, but due to an en-
vironmental factor. Even if the causewere genetic, if it is due to a somatic[, ]
or heteroplasmic variant, then the causal variantmay not have been present in the

Figure 4.1: Diagnostic yield of MitoExome sequencing in two cohorts of pa-
tients with OXPHOS disease. Abbreviations: MCRI, Murdoch Childrens Research
Institute; MGH, Massachusetts General Hospital
sample that was sequenced. Even if the causal variant was in the sequenced sam-
ple, it may not have been prioritized. Some cases of ciliopathies have been shown
to be due to oligogenicity, that is to say multiple heterozygous mutations across
several genes [, ]. It is diﬃcult to prioritize such cases, as the number of
pairs of candidate genes can be quite large (>,, formitochondrial disease).
Similarly, disease may be due to dominant mutations, such as those that enable a
gain-of-function, but it is hard to identify causal variants over the background of
rare protein-modifying variants (~MitoExome variants per individual). Lastly,
even if disease were due to recessive-type variants we may miss them either be-
cause they were a class that was not prioritized (such as splice variants distant
from splice junctions, as in the MTFMT cases in Chapter ), incorrectly ﬁltered
(ie. “common” pathogenic variants) or never called, such as structural variants.
is chapter describes an attempt to expand our analysis of MitoExome data by
including some structural variant calls.

Figure 4.2: Possible failure modes of MitoExome sequencing.
.. S V
Structural variants (SVs) are a diverse class of genomic alterations that encom-
passes all sub-chromosomal changes larger than SNPs and indels. Originally struc-
tural variants were restricted to events >kb [], but more recently it has been
appreciated that events as short as ~bp frequently occur and are in fact more
common than larger events []. Structural variantsmay be balanced, causing no
change in copy number (such as inversion or translocations), or can be copy num-
ber variants (CNVs) such as deletions or ampliﬁcations. Some structural events
are complex and may include a combination of deletions, ampliﬁcations, inver-
sions and/or translocations [].
P
Individuals do not have as many structural variants as SNPs or indels, but such
events are still prevalent throughout the human genome. A typical individual has
about ~, CNVs with a median size of .kb[]. One of the ﬁrst analyses of
large, rare (.-) CNVs in the general population used Illumina BeadArray tech-

nology to survey variants in a cohort of ~, individuals. Variants> kbwere
found in - of individuals and ones greater than Mb were found in - of
individuals []. A follow-up study looked to see howmany of these events were
due to de novo mutations by looking at structural variants in trios []. Events
larger than kb had amutation rate µ = :  CNVs/genome/transmission,
while events > kb were twice as rare with a mutation rate of µ = :   ,
or once every ~ births.
L   
Pathogenic structural variants are not as numerous as pathogenic SNPs or indels;
however, they represent an appreciable proportion (~) of entries in the Hu-
man GeneMutation Database (HGMD).ey are being discovered at a more rapid
rate than SNPs and indels suggesting an ascertainment bias (Table .). Structural
variation has been linked to many human diseases (reviewed in []), both spo-
radic [] and complex []. Examples include left-sided congenital heart disease
[], autism [, ], schizophrenia [, ], Crohn’s disease [, ],
and mitochondrial disease [].
.. M    
e earliest structural variants were discovered by karyotyping using microscopy
of metaphase chromosomes. In the early ’s twomethods of dyingmetaphase
chromosomes to create band patterns enabled discovery of events >Mb in size
[, ]. Since then, a variety of molecular, microarray and sequencing based
methodshave beendeveloped that have increased the resolutionof structural vari-
ant detection by  orders of magnitude to events less than  bases[].

Table 4.1: Human Genome Mutation Database variants stratiﬁed by type.
“Small” events are  bp. While structural variants only account for 10% of entries,
new ones are rapidly becoming discovered.
Type  in Q ()  in Q ()  Growth
Missense/nonsense , () , () 
Splicing , () , () 
Regulatory , () , () 
Small deletions , () , () 
Small insertions , () , () 
Small indels , () , () 
Gross deletions , () , () 
Gross insertions , () , () 
Complex rearrangements  () , () 
Repeat variations  ()  () 
M M
e ability to conjugate DNA to ﬂuorophores in the ’s greatly advanced struc-
tural variant detection. In ﬂuorescent in situ hybridization (FISH) [], ﬂuores-
cently labeled DNA molecules are used to label speciﬁc loci within genomes. As
methods of DNA preparation for FISH have evolved, the resolution limit has ac-
celerated from >Mb to kb [, , , ]. In multiplex-FISH, also known
as chromosome painting or spectral karyotyping, genome-wide libraries of FISH
probes are used to diﬀerentially label whole chromosomes [, , ]. is
advancement enabled the ﬁrst genome-wide screen for gross chromosomal abnor-
malities with resolution < Mb [, ].
e ﬁrst test designed speciﬁcally to detect copy number variants was compara-
tive genome hybridization (CGH). In CGH, reference and sample DNA are labeled
with green and red ﬂuorophores, mixed in equal amounts and co-hybridized to
normal human metaphase chromosomes []. CGH has a modest resolution of

>Mb for low-level ampliﬁcations and deletions and >Mb for high level ampli-
ﬁcations [, ].
M M
Microarray technology radically advanced the detection of CNVs as reviewed in
[]. Both array-CGH [, ] and SNP arrays can be used to detect structural
variations.
Array-CGH is a microarray designed speciﬁcally to perform CGH. By separat-
ing genomic loci on a slide, array-CGH is able to achieve much higher resolution
than traditional CGH. In array-CGH, DNA from a test and a reference sample
are both labeled and hybridized to a two-color microarray. e ratio of intensi-
ties between sample and reference is used to detect ampliﬁcations and deletions.
Early CNV calling algorithms smoothed consecutive ratios and then looked for
series of probes that exceeded a threshold []; however, more nuanced detec-
tion schemes including circular binary segmentation (CBS) [], hidden Markov
models (HMM) [] and wavelet methods [] were later developed.
e ﬁrst human genome-wide array-CGH experiment used an array of bacterial
artiﬁcial chromosomes (BAC) spaced every Mb.  unrelated individuals were
tested and  distinct gains or losses were found.  of these were recurrent
[]. As array-CGH experiments moved from BAC arrays to oligonucleotide ar-
rays, the number of CNVs discovered has drastically increased. To date, there have
been two large-scale high-resolution surveys have used genome-wide array-CGH
to assay copy number variations across the entire human genome. Using a set of
 NimbleGen arrays each comprising ~. million long oligonucleotide probes,
Conrad et al. surveyed  Hapmap samples ( CEU,  YRI) to discover ,

CNVs greater than  base pairs []. Using a set of  Agilent arrays each com-
prising ~Moligonucleotide probes, Park et al. surveyed  individuals from three
Asian populations to discover , CNVs of which , were speciﬁc to Asians
[].
While SNP arrays were not originally designed to detect copy number variants,
intensity values from individual probes have been massaged into revealing vari-
ants. B-allele frequencies from the ratio of two SNP-speciﬁc probes can be used to
reﬁne calls. For instance, stretches of homozygosity are suggestive of a deletion
and stretches of abnormal B-allele frequencies are suggestive of an ampliﬁcation[].
e prevalence of CNVs in human genome has beenmeasured using SNP arrays on
several cohorts [, , ]. A comparative survey of SNP arrays for the detec-
tion of structural variants concluded that while SNP arrays can be used to detect
rare CNVs and genotype common events, their inability to detect balanced events
and bias against probes that fall in segmental duplications limited their ability to
capture a large proportion of genomic variation[].
S M
With advances in sequencing technology, it is now more feasible than ever to de-
tect structural variationona genomic scale. Several strategies exist to detect struc-
tural variation [], including read-depth, pair-end mapping, split-read and se-
quence assembly methods.
• Read-depth (DP): InspiredbyCGHandarray-CGH, thesemethodsuse depth
of coverage proﬁles as a proxy for copy number [, , , , , ].
• Paired-end mapping (PR): Also known as “end sequence proﬁling”, these
methods detect structural variants by scanning for read pairswith abnormal

orientations or gap sizes. Pair-end analysis was ﬁrst conducted on fosmid
clones [, , ], but has since been applied to whole genome data
[, , , ].
• Split-read (SR): Split read strategies also use sequence pair information,
but restrict the analysis to pairs where only one end maps to the reference
genome. e unmapped read is split in half and both ends are realigned
[, , , ]. ’Clipping reveals structure’ (CREST) is a tool that uses
a variant of split reads where both ends of a read pair align to a genome, but
one has an incomplete alignment [].
• Sequence assembly (SA):ese are computationally expensivemethods that
do away with a reference genome and instead align reads to each other to
build up a genome sequence [, , ]. ey are uniquely able to detect
novel sequence insertions.
esemethodswere all used in the structural variant analysis of theGenomes
Project (KG), the largest survey of human structural variation to date. Vari-
ant calling focused on deletions, but insertions and duplications were also inves-
tigated.  methods were used to generate  call sets using a cohort of 
individuals[]. Candidate lociwere veriﬁed either byPCRor genomewide array-
CGH []. e  call sets exhibited a large range in false discovery rates (FDRs),
with  having FDRs greater than the  cutoﬀ (-). Sensitivity of deletion
discovery was estimated to be only  in high-coverage and  in low-coverage
data. e best algorithm, GenomeSTRiP, integrated signals from RD, PR and SR
detection strategies with population level analysis []. Unfortunately, beneﬁts
from integrating population data are not applicable to rare or de novo events.

Recently there have been several eﬀorts to ﬁnd CNVs in targeted sequencing
data [, , , , , , , , , ]. Targeted sequencing data
is more diﬃcult to analyze than whole genome data for two reasons. First, DP
measures are biased and noised by the capture step. Second, non-DP detection
methods require the presence of reads that cover breakpoints, which is unlikely
when only .-. of the genome is captured in a typical targeted sequencing
experiment.
Algorithms diﬀer on their exact implementation, but follow the same two-step
work-ﬂow: a target-by-target investigation a sample’s of the depth proﬁle followed
by a calling step. Initial algorithms were designed to compare pairs of samples
and would use a detailed statistical model of read depth and in order to report
P-values to a caller [, , , ]. Using cohort of samples instead of a
pair enables new opportunities for improved noise reduction. CoNIFER pioneered
the approach of using singular value decomposition and the removal of the top
components in order to reduce noise in the DP measure. XHMM uses CoNIFER’s
noise reduction approach, but claims to signiﬁcantly improve calling by moving
from a threshold caller to a three state hidden Markov model [].
.. G   
In this chapter we used a modiﬁed version of the CoNIFER algorithm to call copy
number variants fromtargeted sequencing experiments. WeassessCNVdetection
performance both on a cohort of samples with known variants and on a cohort of
sampleswith synthetically inserted variants. We then call copynumber variants in
a collection of  patients with suspectedmitochondrial disease who underwent
MitoExome sequencing.

. M  M
.. E  ME D
Targeted sequencing data came from the  Genomes Project (KG)[] andMi-
toExome experiments[]. Exomes from the KGproject were generated by Bay-
lor College Of Medicine, Broad Institute, and Beijing Genomics Institute using ei-
ther Illumina or SOLiD sequencers and a variety of selection platforms. Mapped
read ﬁles were versioned  for SOLiD data and  for Illumina
data. Consensus targets as of  were obtained from the KG FTP site
ftp://ftp.genomes.ebi.ac.uk/. Sensitivity and speciﬁcity were calcu-
lated using a sets of  samples analyzed by both the KG project and array-CGH
[]. Synthetic variants were tested using randomly chosen cohorts of  or 
samples from KG. Discovery was completed on a set of  patients with mito-
chondrial disease, pseudo-obstruction or ataxia that had undergone MitoExome
sequencing of themtDNA and nuclear-encoded genes implicated inmitochondrial
biology, mitochondrial disease, or monogenic disorders with phenotypic overlap.
 of these samples were captured using a second generation MitoExome target
set that covered  genes and were individually sequenced in a single lane of
an Illumina GA-IIx. e remaining  samples underwent selection using a third
generation target set that included  genes and were barcoded and sequenced
on an Illumina Hi-Seq. ird generation targets were used for analysis. Study pro-
tocols were approved by the Partners Human Research Committee. All samples
were obtained with informed consent for sequence analysis and data deposition
into public databases.

.. D   
Depth of coverage was calculated on single samples using the Genomic Analysis
Toolkit v.. using the DepthOfCoverage walker []. By default the GATK
ignores duplicate reads. Walker parameters were set to ignore bases with quality
scores < and reads with mapping qualities <.
.. R D-B CNV D
A copy number variant detection framework inspired by CoNIFER[] was de-
veloped using the Python program language and the iPython, Numpy, Scipy, Mat-
plotlib, Pytables and Pymongo libraries. An initialization step reads and processes
depth data into an intermediate ﬁle that can be used for noise reduction and call-
ing. GATK “sample_interval_summary” ﬁles provide depth counts by target and
the total number of mapped reads. Reads Per Kilobase per Million mapped reads
(RPKMs) were calculated and used to remove probes where the median RPKM
<.. e RPKM matrix of unﬁltered probes is Z-normalized by subtracting the
by-target mean and dividing by the standard deviation. Singular value decompo-
sition is then computed on the entire ZRPKMmatrix. Because rare CNVs are not
expected to contribute much to the noise in the ZRPKM matrix, noise is reduced
by setting a given number of the top singular values to zero and calculating the dot
product of the U, S, and VT matrices to reconstruct a matrix of SVD-ZRPKM val-
ues. e number of components to remove is determined by looking for an elbow
in a Scree plot, a line plot showing the variance in the data explained by each prin-
ciple component. eelbow is automatically detected byﬁnding the point furthest
from a line that connects the beginning and end of the Scree curve. Before calling
CNVs, SVD-ZRPKM values are smoothed over ± or ± probes using weightings

from a Blackman ﬁlter. CNV calls were made from smoothed SVD-ZRPKM values
that exceeded a set threshold.
.. R-B V E
Additional tools were developed to obtain data from aligned read (BAM) ﬁles that
support structural variants using the pysam library. Methods implemented in-
clude pair read analysis by looking for mate pairs where only one end is mapped or
inwhich there is an abnormally large insertion size. Clipped read analysis was per-
formed by ﬁltering for reads whose CIGAR alignment contains two regions, one
that is aligned and another that is soft clipped.
.. P G B
A web-based tool capable of calling structural variants and integrating with Mi-
toExome results was developed with the Python Flask library.
.. C      
Truepositive call setswere obtained fromtheDatabase ofGenomicVariants (DGV)[].
RawGVF formatted ﬁles were converted to bed format via a custom Python script
and translated to hg using the UCSC liftover tool []. Sensitivity was calcu-
lated on rare (in < of samples) variants that overlapped at least  unﬁltered
targets but had less than half of their sequence overlapped by segmental duplica-
tions. It is nontrivial to determine the allele frequency of structural events as their
endpoints are highly polymorphic; variants were considered overlapping if their
minimum reciprocal overlap was at least . Calls were considered being true
positives if at least a quarter of overlapping probes exceeded the calling threshold.

Call sets used for sensitivity analysis were also used to create synthetic variants.
e FPR was calculated on chromosomes ,  and  treating all variants as
true.
. R
.. P  CNV D
P   A-CGH   E
To benchmark the performance of our depth-based CNV calling system, we made
calls in a cohort of  samples whose DNA was analyzed for CNVs by genome-
wide array-CGH[] and also underwent whole exome sequencing as part of the
 genomes project[]. ese samples had  gains and  loss events that met
our ﬁltration criteria of being in at most two samples, having less than half their
sequence covered by segmental duplications and overlapping at least three well
covered targets. e inﬂection point of the scree plot was detected at , which was
chosen as the number of components to remove (Fig. .A). Plots of three putative
ampliﬁcations and deletions before and after SVD noise reduction can be found in
the top two panels of Fig. .B-G. Setting the top singular values to zero signiﬁ-
cantly reduced the variability of the data while having a minimal, but noticeable,
impact on real events. For example, in the loss event overlappingMASP, setting
the top singular values to zero brings NA’s smoothed depth just under the
default calling threshold of :.
Calls made using the default parameters for CoNIFER (smoothing with a Black-
manwindowof ±probes and a calling threshold of .) have a sensitivity of .
for detecting ampliﬁcations and  for detecting deletions. e FPR for both

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Figure 4.3: Performance of CNV detection in a control cohort. (A) Scree plot
revealing the contribution of each principle component in a cohort of 37 control sam-
ples has an elbow at 5. (B-G) Visualization of three ampliﬁcations (left) and three
deletions (right) when processing 37 samples without (top panels) or with (middle
panels) SVD noise reduction or when fully processing 200 samples (bottom panels).
The graphed CNV detection threshold is ±1.5. (H) Scree plot for 200 samples has
an elbow at 15. (I) ROC curve of CNV detection in 37 samples when processing 37
or 200 samples. (J) ROC curve of CNV detection when processing 200 total samples
and using smoothing over ±7 or ±4 probes. Abbreviations: ROC, Receiver operating
characteristic; W, Window size for smoothing

ampliﬁcations and deletions is ., which for the ~, targets in an
exome would amount to about one call per sample. Relaxing the calling threshold
to . increased the sensitivities to . and .; but also increased the FPR
roughly -fold. A full receiver operating characteristic (ROC) curve can be found
in (Fig. .I).
e SVD noise reduction strategy should work better as more samples are con-
currently analyzed and the systematic noise becomes more evident. CNV detec-
tion was repeated after adding additional samples from the  genomes project
such that a total of  samples are analyzed. e inﬂection point of the scree plot
was detected at  (Fig. .H). Running the analysis with  verses  samples
does not seem to have a signiﬁcant impact on signal to noise in detecting the six
example variants (Fig. .B-G, bottom panel vs middle panel) or on performance
when viewed as as ROC curve (Fig. .I). We were concerned that the algorithm’s
default parameters use excessive smoothing as the SVD-RPKMvalues are averaged
over a window of ± probes and < % of our variant set spans such a distance.
Changing the window to ± probes slightly improved calling performance on syn-
thetic variants (Fig. .J); however, no matter how these samples are processed,
sensitivity for ampliﬁcations and deletions maxes out at around  and  re-
spectively.
P   
To better understand why these sensitivities are so low, we artiﬁcially inserted
the true positive set of variants into a cohort of  randomly chosen samples.
e read depths overlapping the  ampliﬁcations and  loss events above were
modiﬁed by  (“mild”, .X change),  (± copy) or  (“severe”, X

change) simulating a partial, single or many copy number change (Fig. .A-F).
“Mild” variants simulate the situation where that may not be a : correspon-
dence between copy number and sequencing depth, perhaps due to non-linearities
during DNA target capture. In such instances, only . of ampliﬁcations and
. of deletions were recovered at a threshold of :. Calls made after inserting
± copy variants faired better with sensitivities of . for detecting ampliﬁca-
tions and . for detecting deletions using that threshold. A full ROC curve
can be found in (Fig. .G). Unlike for the real variants, changing the window to
± probes signiﬁcantly improved calling performance on both this set of synthetic
variants (Fig. .H) and another set inserted into a diﬀerent cohort of  sam-
ples (Fig. .I), suggesting that the default settings over-smooth the data.
.. CNV D ME 
We next applied CNV detection to  individuals with suspected mitochondrial
disease who had subsequently undergone MitoExome sequencing at MGH. To fa-
cilitate variant interpretation, we developed CNVisualizer, a web interface that
integrates CNV detection with MitoExome sequencing variants and clinical sum-
maries (Fig. .). A conservative call-set of  CNVs was made after removing
 singular values using a threshold of . and smoothing ± probes. Almost half
of these variants were in genes known to commonly harbor copy number poly-
morphisms such as PDPR (N=)[], GTPBP (N=), ACOT (N=) and HPR
(N=). Many CNVs were reported to be larger than the depth data suggested due
to smoothing. In addition to evaluating these variants, a liberal call-set was made
using a threshold of . and smoothing over ± probes. A feature was added to
CNVisualizer that automatically detected genes with multiple variants. While the

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Figure 4.4: Performance of CNV detection of synthetic variants. (A-F) Visual-
ization of the three ampliﬁcations (left) and three deletions (right) from Fig. 4.3B-G
when artiﬁcially inserted into a cohort of 200 samples. The top panel shows a “mild”
CNV which models a half gain or loss. The middle panel represents a copy number
gain or loss of one copy. The bottom panel shows a “severe” CNV caused by a 40X
gain or loss of depth. The graphed CNV detection threshold is ±1.5. (G) ROC curve
of CNV detection of synthetic CNVs. (H-I) ROC curve of CNV detection of two sets
synthetic gains or losses of one copy using smoothing over ±7 or ±4 probes in two.
Abbreviations: ROC, Receiver operating characteristic; W, Window size for smoothing

liberal call-set had ~ events per sample (, total), analysis could be focused
on the few recessive-type candidates in each sample. Additionally, depth proﬁles
for genes harboring known pathogenic variants were manually investigated. Ex-
emplary variants and cases are discussed below.
D      K D
Krabbe Disease (globoid cell leukodystrophy, OMIM ) is a progressive
disease of demyelination caused by recessive mutations in galactocerebrosidase
(GALC), a lysosomal enzyme involved in the catabolism of galactosylceramide.
Most cases present during infancy with rapid central and peripheral nervous sys-
tem degradation, but - of cases are late-onset and can appear as late as
the ﬁfth decade of life []. Presentation of these late onset cases is highly vari-
able. About  of both infantile and adult patients have one or two copies of
a “common” kb deletion that overlaps the seven exons of GALC[, , ].
We detect a CNV consistent with this variant in one patient, HL (Fig. .A).
In addition to detecting a reduced depth signature, variants from MitoExome se-
quencing provided further support for this call. e patient has six variants over-
lapping the deletion that all appear homozygous (c.A!G, c.+C!G,
c.A!T, c.T!C, c.A!G, and c.C!T) and is heterozygous for
the “T” allele known to be associated with the deletion (at c.C!T under
current nomenclature[]).
HL is a French Canadian female who presented at age  with weakness,
muscle pain and exercise intolerance and underwent a muscle biopsy. Light mi-
croscopy of the biopsy revealed scattered small and round angulated ﬁbers that
varied in size. We do not detect any additional rare-protein modifying GALC vari-

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Figure 4.5: CNVisualizer is a web application that can make CNV calls and inte-
grate them with MitoExome sequencing results and clinical phenotypes to facilitate
variant interpretation. (A) The sample view automatically detects recessive-type can-
didates and provides relevant links to GeneCards, UCSC Genome Browser and DGV.
(B) Each CNV call is linked to a plot that facilitates visualization of the supporting
depth data and provides controls to alter calling parameters.

ants in this patient, but it is interesting to note thatmutations inGALChave previ-
ously been implicated in altered muscle ﬁber diameters[] and there have been
reports of psychomotor [] and cognitive eﬀects in carriers[]. Detection of
this variant underscores the importance of performing CNV detection for genetic
diagnostics - especially in diseases with common deletions, such as Krabbe Dis-
ease.
MB       HL
HL had an ampliﬁcation of the distal quarter of the short arm of chromo-
some  (p!pter) (Fig. .B). Full trisomy of p is a clinically recognizable
multiple congenital anomaly/mental retardation syndrome[]. To date, there
have been ﬁve case reports of submicroscopic trisomy  ranging in size from .-
Mb in pure form [, ] or in tandemwith large deletions in q[], q[]
or p[]. Our female patient presented as an adolescent with many symptoms
shared by other patients with submicroscopic trisomy p such as GI reﬂux[],
cerebellar hypoplasia [], optic nerve defects [], learning disability [, ,
, , ], hypotonia [], and immune deﬁciencies[]. She additionally
presented with migraine, seizures, balance problems, autonomic nervous system
dysfunction,muscle tremors, twitching, spasms, dysmenorrhea, bone density loss
and disc desiccation. e next steps for this patient are to conﬁrm this variant
which should be possible through karyotyping and test if it formed de novo by in-
vestigating parental DNA.

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Figure 4.6: CNV Detection in MitoExome patients. (A) An event consistent
with the 30kb deletion found in about half of Krabbe Disease cases is found in
HL1173. (B) A large subtelomeric ampliﬁcation with a breakpoint between ATP4C1
and ECHDC3 is detected in HL1107. (C) A potential single exon deletion in PHYH
in HL1033. (D) A candidate deletion of the last exon of MTFMT in HL1254. (E) A
candidate deletion of the second exon of MTFMT in SM-1HOMR. (F) A 12kb dele-
tion of exons 10-13 of HSD17B4 in HL1228 supported by a reduced depth signature
and read pairs with long inserts.

P R   HL
Refsumdisease (OMIM) is a disorder of impaired alpha oxidation of fatty
acids which leads to the buildup of neurotoxic phytanic acid. About  of cases
are caused by recessive mutations in phytanoyl-CoA hydroxylase (PHYH), a per-
oxisomal enzyme[]. In PHYH in sample HL, we detect an exon in the
promoter region is covered by only three read pairs (Fig. .C) and the patient
additionally harbors a variant (p.RQ) previously shown to cause partial en-
zyme deﬁciency[]. If Refsum disease is left unnoticed through childhood, it
may present in the teens, often after an infection, with symptoms including acute
weakness, ataxia, sensory neuropathy, cardiomyopathy and ichthyosis[]. Our
patient presented at age  after a bout of ﬂuwithmuscle pain in her lower left ex-
tremities. e patient went on to develop exercise intolerance, heart palpitations,
mitral valve prolapse, tinnus in her right ear, dry eyes, hot and cold intolerance,
complexmigraines and stroke. GI symptoms were notable for Crohn’s disease and
stress incontinence. An ultrasound performed on her sural nerve  years later
was consistentwith demyelination. While bloodworkwas not notable for elevated
levels of phytanic acid, there have been case reports of Refsum Disease with nor-
mal blood phytanic acid levels []. Given the phenotypic overlap of this patient
with Refsumdisease, phytanoyl-CoA hydroxylase enzyme activity levels should be
tested and this deletion should be conﬁrmed and phased. If a diagnosis can be es-
tablished, further symptoms can be prevented by reducing dietary intake of free
phytanic acid by avoiding dairy, ﬁsh and meats[].

T   L S   MTFMT
In two cases with Leigh syndrome and one copy of the pathogenic p.SL variant
in MTFMT described in Chapter , we detect exons of MTFMT with low coverage.
We have previously shown that recessive mutations in MTFMT cause Combined
Oxidative Phosphorylation Deﬁciency  (OMIM ). HL presented
in infancy with Leigh syndrome, optic atrophy, ataxia and elevated lactic acid in
cerebral spinal ﬂuid. e patient has severely reduced coverage of the last exon
ofMTFMT (Fig. .D). SM-HOMR is a male who presented with developmental
delay, ataxic gate, dyspraxia of upper limb, and Leigh syndrome. He has low cover-
age of the second and fourth exons of MTFMT (Fig. .E). Evidence of a deletion
in this patient is weaker than in HL; the low coverage in the fourth exon is
likely explained by the p.SL variant, and the reduction in coverage of the sec-
ond exon is modest. Before a diagnosis can be established in either of these cases,
these variants will need to be conﬁrmed and phased.
HSDB-  HL
In one case, wemake a newmolecular diagnosis. HL is a  year-old male pa-
tient with cerebellar ataxia, peripheral neuropathy, azoospermia, and mild hear-
ing loss. We detected a kb heterozygous in-frame deletion of exons - of
HSDB (Fig. .F) that was compounded with a missense variant (p.AV) at
a highly conserved residue predicted to impact NAD-binding (Fig. .A).e dele-
tion is supported by both PR and SR signals in the form of reads with long inserts
and clipped reads. Inspection of the clipped reads reveals that a single adeninewas
inserted into the deletion site. is deletion is indicative of a non-homologous end
joining following a double strand break as it lacks extensive regions of homology

WSRM 
APNAGSRM 
APNAGSRM 
APTAGSRL 
VPTAASRM 
APIAASRL
APLARSRM 
APFA
VghydroxyoxyacylgCoA
dehydrogenase-
V>:-
>genyolgCoA-hydratase SCP>-
/>>- wV/aa-
Human-
Mouse-
Zebrafish
Fruit-fly-
Slime-mold-
Yeast-
P. aeruginosa
c#_8wC>T
p#AY9/V-
PTS-Ingframe-deletion-
chr_:YY88>_cY/gYY88VwVV:del_insA
c#wY_gY>cwdel
p#>V9_:cVdel-
HSD17B4 
Mother
Sister
Proband
AlaAsn Gly
A A AT G C/T G G G
Mother SisterProband
D
V8/bp
w8_bp
Y>#V-kb-delet ion VY/
:/9 wc
TTTTCTCTTATTAGTTTTCTaGTGACCTGAAATTACTAGC
wt
del.
CxT
wtxwt
nd
nd
CxC
delxwt
CxT
delxwt
NADgbinding- 8A B
C
Figure 4.7: Conﬁrmation and phasing of HSD17B4 variants in HL1228. (A)
HSD17B4 gene structure showing multiple enzymatic domains and the location of the
p.A196V variant at a conserved residue and 12kb in-frame deletion. (B) Mutations
in HSD17B4 in HL1228 and family members. The proband is the only member with
evidence of both variants. (C) Conﬁrmation of p.A196V variant in the proband and
mother via Sanger sequencing. (D) Conﬁrmation of the 12kb deletion in the proband
and sister, but not mother. Abbreviations: PTS, peroxisomal targeting signal; SCP,
sterol carrier protein
at both ends of the breakpoint and has the insertion of a nucleotide []. Analy-
sis of familial DNA conﬁrmed the presence of the deletion and revealed that the
two mutations were compound heterozygous, with the missense variant inher-
ited from the mother and the deletion, which was heterozygous in the HL’s
healthy sister, likely inherited from the father, from whom DNA was unavailable
(Fig. .B-D).
HSDB, also known as D-bifunctional protein and multi-functional protein
, is a peroxisomal enzyme that catalyzes multiple steps of beta-oxidation of very

long chain fatty acids. e protein consists of three domains: an N-terminal de-
hydrogenase domain, a central hydratase domain, and a C-terminal sterol car-
rier protein (SCP) domain. e ﬁnal three amino acids form the peroxisomal tar-
geting signal (PTS). After peroxisomal import, the kDa full-length protein is
proteolytically cleaved near amino acid  to yield a kDa dehydrogenase sub-
unit and a  kDa hydratase/SCP subunit. Recessive mutations in HSDB are
the known cause of D-bifunctional protein deﬁciency (OMIM ), an au-
tosomal recessive disorder of peroxisomal fatty acid beta-oxidation that is gen-
erally fatal within the ﬁrst  years of life[], and have recently been identiﬁed
in two sisters, diagnosed with Perrault syndrome (OMIM ), who exhib-
ited severe sensorineural deafness, ovarian dysgenesis, peripheral neuropathy and
ataxia[]. Retrospective review of metabolic testing from our patient revealed
alterations of long- and very-long chain fatty acid metabolism consistent with
a peroxisomal disorder, including elevated ratios of pristanic:phytanic acid and
arachidonic:docosahexaenoic acid. Due to the phenotypic similarity to a previous
case, the predicted severity of the HSDB mutations, and the metabolic evi-
dence of peroxisomal dysfunction, the patient was given a diagnosis of HSDB-
deﬁciency. A full case report on this patient is in preparation.
. D
We have shown that is is possible to call copy number variants from targeted se-
quencing experiments and that these variants can lead tonewmolecular diagnoses
of disease.
We show that we are able to recover a portion of known deletions and, to a
lesser extent, ampliﬁcations in a control cohort. ere are a number of reasons

why we may not have detected more of these bona ﬁde variants. One possibility
is that these variants may not all be real. Multiple attempts to call copy number
variants from the same samples often produce callsets with poor concordance [,
, ]. Our experience from recalling synthetic variants, especially attenuated
ones, underscores the diﬃculty in calling copy number variants from depth data.
A recent paper presents a similar sensitivity of  of detecting CNVs using the
 Genomes exome data []. ese data have been produced on multiple
sequencing platforms in multiple sequencing centers, which could contribute to
variability in depths. Lastly, it could be that increased coverage or larger sample
cohorts are required to make accurate calls. While we show that increasing the
cohort size from  to  samples did not signiﬁcantly improve variant calling,
it is possible that an even larger cohort could improve performance.
Morework remains in improving performance of structural variant calling from
targeted sequencing data. For instance, breakpoints can bemore accurately identi-
ﬁed and small events can be more readily detected by switching from a smoothing
method that treats all data points as equal to one that weighs data based on dis-
tance [] or on their coverage. Call quality may also be improved bymoving from
thresholding to a more advanced calling algorithm such as CBS[, , ,
] or aHMM[, , , ]. Further improvements to structural calling tools
can bemade by integrating signals beyond just depth. At least two structural vari-
ant callers, GenomeSTRiP and GSAVPro, integrate read depth signals with pair
end signals [, ]. e deletion in HSDB in HL is an example of a
variant that has an abundance of supporting information from raw reads and the
Krabbe disease deletion in HL was supported by B-allele frequencies and a
SNP in linkage. Further data integration opportunities exist if additional data is

collected, such as array-CGH, SNP arrays [] or emerging technologies like mi-
croﬂuidic nanochannel-assays of DNA length distributions []. e design of
a sequencing experiment can also be altered to improve structural variant detec-
tion. Increasing depth and adding more baits for bases ﬂanking exons should im-
prove the signal from variants and capturemore breakpoints, though for themost
complete coverage, samples should undergowhole genome sequencing, preferably
with de novo assembly.
We are able to make one ﬁrm and four tentative genetic diagnoses in our co-
hort of  patients with mitochondrial and related disease. Our strategy to au-
tomatically detect recessive candidates using CNVisualizer enabled the discovery
of several potential single exon events that would otherwise have gone undiscov-
ered. Many of these variants need to be conﬁrmed and phased before a link to
pathogenicity can fully be established. Given the prevalence of large insertion and
deletion events in HGMD, one may expect more than ﬁve examples of potentially
pathogenic variants in a cohort of over  individuals; however, given our lim-
ited sensitivity of calling variants in a control cohort and for synthetic variants,
it is likely that there are more CNVs in this cohort that have yet to be discovered.
ese results underscore the importance of looking beyond SNPs and indels when
investigating the genetic causes of disease.
. M I
.. A C
is study was conceived and designed by S.G.H. and V.K.M. Analysis was per-
formed by S.G.H, with the exception of the HSDB case which was assisted by
D.S.L. Variant conﬁrmation was performed by D.S.L. e manuscript was written

by S.G.H. All aspects of the study were supervised by V.K.M.

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Implication and Future Directions
T   next-generation sequencing, we have investigated the ge-netic basis of mitochondrial disease in approximately  patients. We
have identiﬁed three new disease genes and have presented several additional can-
didates. Using patient samples deﬁcient in MTFMT, we were able to show that
formylation is required for mitochondrial translation. Lastly, we were able to re-
analyze our targeted sequencing data and detect copy number variants leading to
the discovery of a case of HSDB deﬁciency. is work has implications for our

understanding of mitochondrial biology and personalized medicine.
. I
.. D    
We present strong evidence that recessive mutations in AGK, NDUFB and
MTFMT cause mitochondrial disease and present  additional prioritized can-
didates. Since publication of these ﬁndings, other groups have found individuals
with pathogenic variants inAGK[] andMTFMT[, ] and in one candidate,
EARS[].
.. D    
Genetic testing for mitochondrial disorders has historically not been terribly suc-
cessful. It has been myopic in that typically only the mtDNA or a handful of can-
didate disease genes would be sequenced. Recently, several companies including
Courtagen and GeneDx have begun to oﬀer more comprehensive genetic tests
modeled afterMitoExome sequencing. Another option is exome sequencing; how-
ever, standard exome kits do not reliably capture the mtDNA. To remedy this, a
group developed a “: Mito-Plus Whole-Exome” that combined an exome kit
with additional probes for  MitoExome genes and the mtDNA[] and Baylor
College ofMedicineMedicalGenetics Laboratories currently oﬀers anExome+mtDNA
test (http://www.bcm.edu/geneticlabs/?pmid=). It is exciting to see
such tests being oﬀering to patients so quickly.

. F D
.. C     
is work addressed the so called “, interpretation” that threatens the
“, genome”[]. In the course of investigating theMitoExomes of ~ in-
dividuals, approximately half amillion variantswere detected andprocessed. Such
a feat was accomplished largely through a series of bioinformatic scripts that in-
tegrated data from several sources and generated user-digestible reports. In order
to dive into cases, I prototyped a web-based data exploration tool, CNVisualizer.
While some believe that advances in CNV detection algorithms will “eventually
eliminate the need for chromosome microarrays as a separate test”[], simula-
tions with synthetic variants suggest that targeted sequencing data is inherently
limited and is not a suitable replacement formicroarrays. In clinical sequencing, it
is common for a patient to undergo several tests. As more patients undergo more
genetic and “omic” tests, tools that integrate and automate the analysis of these
data will need to be developed.
.. F    
It has been estimated that exome strategies are successful in identifyingMendelian
disease genes in  of projects[]. is is consistent with our experience in
Chapter  where we were able to identify candidates underlying genetic defect in
 of  () infants withmitochondrial oxidative phosphorylation disease. But
what about the rest? Several possibilities exist andwere discussed in the introduc-
tion of Chapter  (Fig .). Some of these possibilities can be explored with new
informatics. For example, the possibility of additional splice mutations is exciting

as it has been estimated that between [] and [] of disease-causing
mutations aﬀect splicing. An example of one suchmutation is the p.SL variant
in MTFMT, which we showed caused skipping of an exon (Chapter ). Progress
is being made on algorithms that detect such mutations [], but their sensi-
tivity/speciﬁcity are not yet ready for prime time on a genome-scale[]. In-
stead of using informatics approaches, generating additional genetic or pheno-
typic data may enable better evaluation of sequencing failure modes. MitoExome
sequencing does not fully detect the wide array of informative variants that live
within a patient mtDNA or nuclear genome. Whole genome sequencing would be
ideal as it would not only detect the untargeted SNPs and indels, but would addi-
tionally improve structural variant detection by providing data from breakpoints;
however, it is still expensive to apply on large cohorts. Even with whole genome
sequencing, coverage of the mtDNA would not be complete as most sequencing
projects suﬀer from limited ability to detect low level heteroplasmic variants, due
to the presence of nuclear mitochondrial DNA homologs (NUMTs), which gener-
ate short reads that are indistinguishable from ones generated from mtDNAs. A
report recently showed that single amplicon long-range PCR instead of hybrid cap-
ture reduces the background fromNUMTs and increases sensitivity to heteroplas-
mic mtDNA mutations[]. Another PCR-related strategy, long padlock probes
can also be used to supplement coverage for nuclear exons. A set for  exons
from  nuclear-encoded mitochondrial genes has recently been created[].
Lastly, microarrays could be deployed to improve detection of CNVs and mtDNA
deletions. Two groups have presented array designs that cover the entire mtDNA
and ~ nuclear genes[, ], which have enabled the discovery of single exon
deletions[]. With current array synthesis technologies, single sample arrays

have beendeveloped that cover the entire exome[]. AMitoExome target ismuch
smaller than an Exome, and, in theory, a MitoExome array can be designed that
can process eight samples using a single slide.
On the phenotypic front, it should be possible to molecularly characterize pa-
tient cell lines in order to understand which mitochondrial processes are aﬀected.
“Central Dogma” phenotyping can be applied to look for defects in mtDNA copy
number, the expression and processing inmitochondrial RNAs and the expression
and assembly of respiratory chain complexes. A recent study introduced the con-
cept of an integrative personal omics proﬁle that used genomics, metabolomics
and transcriptomics to provide medical insight []. Such an approach could also
be fruitful in a research setting. Metabolic proﬁling could be used to detect en-
zyme deﬁciencies. Expression analysis of RNA-sequencing data can detect dys-
functional regulatory pathways and allelic expression[, , ] can be mea-
sured which can uncover heterozygousmutations that are expressed in a homozy-
gous or near-homozygous state[].
.. E    
More candidate mutations would be instructive; however, sequencing projects
have already produced a backlog of candidates whose pathogenicity has yet to be
proven. In this thesis, pathogenicity of genes was proven via complementation
studies in patient cell lines or recurrent hits in phenotypically similar patients.
Cell line studies can only be completed if patient material is available and it shows
a phenotype. Even if such materials are available, getting a rescue is a laborious
and ﬁnicky process. In some cases, yeast have been used to prove pathogenicity
[], but this is only an option if a homologue exists. e ability to rapidly gen-

erate DNA editing reagents, such as those based on zinc-ﬁngers nucleases[],
transcription activator-like eﬀector nuclease (TALENs) [] or clustered regu-
larly interspaced short palindromic repeats (CRISPR)[], will enable studies in a
variety of model systems ranging from human cell lines to model organisms. Phe-
notypes can be enhanced with stem cell technologies, such as MyoD transforma-
tion of ﬁbroblasts into myotubes[]. Rescue experiments will still be laborious
and given the proliferation of sequencing, the future of variant evaluation may
come from statistical tests on large cohorts of phenotyped individuals. Such co-
horts will arise both from research eﬀorts, many of which are available via the
database of Genotypes and Phenotypes (dbGAP)[], but also from the health
care industry, which is rapidly becoming digitized [].

A
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A.. M OXPHOS-

Four of the  nuclear OXPHOS disease-related genes recently reviewed [] did
not have evidence of mitochondrial localization in the MitoCarta compendium
[]: TAZ, PUS, RRMB, TYMP. Manual review of these genes conﬁrmed uncer-
tain or non-mitochondrial localization.

A.. DNA 
Several diﬀerent approaches were compared for mtDNA sequence alignment and
analysis. Since the nuclear genome has multiple nuclear sequences of mitochon-
drial origin (NuMTs), care must be taken in alignment and identiﬁcation of het-
eroplasmic variants. On average, nuclear exons show X whereas the mtDNA
has ,X coverage, reﬂecting the high number of mtDNA copies per nuclear
genome in the sampled tissues.
When reads were aligned to the entire reference genome GRCh (including
mtDNA sequence NC_),  of the reads aligned to the mtDNA aligned
uniquely while the remainder had an alternative alignment of equal score. us
the vast majority of mtDNA-aligned reads are expected to be indeed derived from
the mtDNA rather than a NuMT. However, we observed that sequence polymor-
phisms could cause thousands of reads to erroneously map a NuMT instead of the
mtDNA. Sincewe aimed to comparemtDNA sequence and coverage across individ-
uals, we chose to align all reads to the mtDNA to avoid diﬀerences in alignment
due to polymorphisms. From the number of NuMT sequences in the reference
genome and the extremely high depth of mtDNA coverage, we estimated that at
least  of reads aligned to the mtDNA were derived from the mtDNA instead
of any NuMT (data not shown). is estimation was consistent with the variant
data that showed that the vast majority of potential variants were supported by
<  of reads. erefore we only analyzed variants present at >  of reads,
consistent with previously methodologies[].

A.. DNA   
mtDNA deletions or rearrangements were detected through de novo mtDNA as-
sembly using a modiﬁed ALLPATHS assembly approach[]. Reads aligned to
the mtDNA were randomly downsampled to X coverage for computational
tractability. Errors in reads were corrected using the ALLPATHS-LG[] error cor-
rection algorithm. Next a k-mer graph[] was constructed (k=), and ﬁltered
using four steps:
. Removal of low coverage edges. At each graph vertex that had two edges (ei-
ther entering or exiting), any edge supported by>  fold fewer reads than
the other edge was removed.
. Removal of small components. Components of the graph containing less than
 k-mers were discarded.
. Removal of all-C edges. Edges whose sequence consisted entirely of Cs were
presumed to be artifacts and discarded.
. Removal of hanging ends. Edges of length <  k-mers for which one end
was a source or sink of the graph were removed.
e resulting assembly consisted of a directed graph, with a DNA sequence as-
signed to each edge. Each assembly wasmanually inspected to identify alterations
supported by>  of aligned reads.
A.. M  - 
Nine genes were previously reported to cause dominant-acting OXPHOS disease:
POLG, POLG, Corf, RRMB, SLCA, OPA, CYCS, MFN, HSPD. We man-

ually inspected all rare, protein-modifyingheterozygous variants orHGMDdisease-
associated alleles in these nine genes with the hypothesis that such heterozygous
variants might cause disease. We would expect to detect . such variants in pa-
tients by chance, given that we observe  such variants within the  healthy
control individuals (including  variants associated with a phenotype inHGMD).
In our  patients, we detected six rare, protein-modifying or HGMD variants
in the nine dominant-acting genes and in none of the cases was the observed
patient phenotype consistent with the previously reported phenotype for dom-
inant mutations. Two individuals harbored MFN variants previously associated
with Charcot-Marie-Tooth in HGMD: p.GR [] and p.VI[]. However,
existing reports of these variants did not provide any evidence of pathogenicity,
and furthermore the severe phenotypes of our two cases were not consistent with
previously reported symptoms (details provided in next section). ree individ-
uals harbored previously unreported mutations in genes known to cause autoso-
mal dominant progressive external ophthalmoplegia (adPEO): OPA:p.RH and
Corf:p.PL. None of the cases showed symptoms consistent with adPEO.
Individual P, from a consanguineous Lebanese family, harbored a previously
unreported heterozygous POLG:p.AV variant of unknown signiﬁcance. us,
there is no strong support that any of these heterozygous variants are likely to
cause the severe disease observed in our patients.
A.. A      
We carefully inspected all variants which were previously associated with any dis-
ease in HGMDorMITOMAP (ACMG category  variants). Supplementary Table 
lists the  such variants with allele frequency <., including  in autosomal

genes,  in mtDNA genes and  in X-linked genes. Of the autosomal variants, 
of  variants were regarded as unlikely to be pathogenic in the patient(s) they
were found in for the following reasons:
.  variants had been reported in autosomal recessive disorders with diﬀer-
ent clinical presentations to the patient and were heterozygous variants in
patientswith no othermutation identiﬁed in that gene (in thePINK, CPT,
ACADM, SLCA x , CPS, DHGDH, AMT,MUT, GLDC, ACADSB, TCIRG,
ACAD, SUOX, SPG x , ALDHA, FECH, GCDH and ADSL genes).
. One patient (P) was homozygous for a reported ACADSB p.EK vari-
ant, but thismutationhas only been reported in biochemical newborn screen-
ing and showed no clinical symptoms attributable to the enzyme defect up
to  years of age [].
. A WFS heterozygous p.KQ variant present as a single heterozygous
variant in an isolated case of sensorineural hearing impairment[] was
present as a single heterozygous variant in two patients (P, P) with
early onset cardiomyopathy or Leigh syndrome, respectively. It was also
present as a heterozygous variant in two sets of healthy control individuals
at . and . allele frequency.
. An HTRA heterozygous p.GS variant previously reported as a risk fac-
tor for Parkinson disease [] was heterozygous in one patient (P) with
a markedly more severe phenotype. It was also present as a heterozygous
variant in one of our control groups at . allele frequency.
. An ELAC heterozygous p.RQ variant listed in HGMD as being linked
to prostate cancer was not interpreted as being a risk factor in the original

publication[]. It was heterozygous in one patient (P).
. AnMFN heterozygous p.GR variant was described [] as a previously
reported missense mutation and listed in their table on molecular ﬁndings
but also in a polymorphisms table. Pathogenic MFN mutations typically
cause autosomal dominantCharcot-Marie-ToothNeuropathy, TypeA. e
pedigree described two aﬀected members but only the proband appears to
have been tested. e previous report [] described this variant as a poly-
morphism, having found it in  of  control chromosomes but not in
MFN patients. is variant was present as a single heterozygous variant
in one patient (P) with a severe leukodystrophy.
. An MFN heterozygous p.VI variant was reported in the proband of a
family with an autosomal dominant history of peripheral neuropathy []
but other familymemberswere not tested. is variant was present as a sin-
gle heterozygous variant in one patient (P) with a severe leukodystrophy.
e p.V residue is poorly conserved (/ species) andwas present as a
heterozygous variant in two of our control groups at . and . allele
frequency.
Of mtDNAvariants reported as disease-associated inMITOMAP, only  (m.C>T
in theMTND subunit gene) was listed as conﬁrmed as it was reported as a homo-
plasmicmutation in familieswith adult-onset Leber’sHereditaryOpticNeuropa-
thy and spontaneous recovery of vision []. However, analysis elsewhere sug-
gests it lacks evidence of pathogenicity[]. It was present in one patient (P)
with a severe multisystem disease and combined OXPHOS complex I, III and IV
deﬁciency, making it unlikely to be causative in this patient. e other  reported

mtDNAmutations inMITOMAPwere not classiﬁed as conﬁrmed, lacked evidence
of pathogenicity, were associatedwith diﬀerent clinical and enzyme abnormalities
to those present in the patients identiﬁed in this study, and were present in the
mtDB database at allele frequencies of . to .. us these variants were
regarded as unlikely to be causative in our patients. Two patients had mutations
in X-linked genes that had previously been reported as pathogenic in HGMD. One
patient (P) was a girl with a heterozygous synonymous ABCD p.RR mu-
tation. ABCD mutations typically cause X-linked recessive adrenoleukodystro-
phy and are an unlikely cause of the lethal neonatal mitochondrial disease found
in P. e other reported X-linked mutation was an in-frame bp deletion in
OTC reported previously in a case of late-onset hyperammonemic coma[]. is
hemizygous indel was present in a boy (P) who manifested symptoms of OTC
deﬁciency including orotic aciduria, hyperammonemia plus borderline low OTC
activity in liver. However, this OTC deﬁciency alone did not explain the sever-
ity of his neurological deﬁcit given quick resolution of hyperammonemia nor his
combined OXPHOS complex I, III and IV defect in skeletal muscle with normal
OXPHOS activities in liver.
us only  of the  reported pathogenic variants identiﬁed in our cohort
appeared likely to explain the phenotype of the patients they were identiﬁed in,
namely one homozygous TSFM variant found in two patients, two POLG variants
found in one patient and a heterozygous BCSL variant found in one patient in
compound heterozygosity with a novel variant as described in the Results section
and Table .
ExtrapolationofMitoExomediagnostic eﬃcacy in retrospective cohort Patients
selected for sequencing were refractory to molecular diagnosis using traditional

approaches. To estimate the eﬃcacy of our approach on unselected samples, we
analyzed a retrospective cohort of  unrelated patients with biochemical evi-
dence of a “deﬁnite” infantile OXPHOS disease from the Murdoch Childrens Re-
search Institute laboratory, which performs OXPHOS diagnostic tests for most of
Australia and New Zealand. is cohort contained  of the samples sequenced in
this study as well as  cases with molecular diagnoses established through tra-
ditional methods such as mtDNA sequencing, candidate gene sequencing, family
studies, orNGS of Complex I candidates[](Fig. A.A).ese  cases included
 nuclear gene diagnoses ( unique genes) and mtDNA diagnoses ( unique
genes/deletions), with the most common mutations in POLG ( cases), SURF
( cases), mtDNA site m.T>G ( cases) and mtDNA site m.T>G (
cases). e  cases encompassed  causal alleles corresponding to  unique
variants, where each homozygous variant represents two causal alleles.
Howmany of the  known causal alleles would have been detected and prior-
itized by MitoExome sequencing? Since MitoExome sequencing showed high and
reproducible coverage across samples, we used the observed coverage to roughly
estimate which of the  known causal alleles would have been detected. We
assumed all SNVs and short indels (<bp) would be detected if supported by at
least  reads (mapping quality > and base quality  ) in half of the  se-
quenced individuals. Variants were assumed to be undetected if coverage <X,
indel length > bp, or nuclear deletion >bp. Using these assumptions, we es-
timated detection and prioritization of  of the  unique variants,  of the
 causal alleles, and estimated diagnoses in  of the  cases (Fig. A.B,
D, E, F). We note that all four variants poorly covered by MitoExome technology
are nowwell-covered by newer hybrid selection technology, however current tech-

nology would most likely miss or not prioritize three large nuclear deletions, one
splice variant located bp from an exon boundary, and one large indel (SURF:
c._delinsAT).
We next extrapolated theMitoExome results from the  sequenced patients to
the  remaining index cases that lacked a molecular diagnosis. Together, these
analyses suggest that MitoExome sequencing would enable molecular diagnosis
in roughly  of cases with infantile OXPHOS disease and would provide poten-
tial candidate mutations in a further  of cases requiring additional follow-up
(Fig. A.C).
A.. V V, P,  C A
All prioritized variants detected inpatientswere independently validated bySanger
sequencing (/ variants validated), and compoundheterozygous variantswere
phased though sequencing cDNA (GFM), clonedDNA (BCSL,Corf,MTHFDL),
familial DNA (GFM, AGK, EARS), or by a molecular haplotyping approach de-
tailed below (ACAD, AARS, POLG, TYMP). / putative compound heterozy-
gous variantswere conﬁrmed and instances are not yet phased, includingACOX
and ALDHB. We note that the candidate genes ACOX and ALDHB harbor
variants in patients with an established diagnosis in known disease-related genes.
Two heterozygous variants in MRPL were determined to be on the same ma-
ternal haplotype and therefore this gene was not listed as a prioritized candidate.
e Corf variant was determined to be an artifact of whole genome ampliﬁ-
cation (WGA) since it was present inWGADNA but absent in genomic DNA based
on Sanger sequencing.

DNA  RNA   DNA 
DNAwas isolated from cultured ﬁbroblast cells or blood using a Nucleobond CB
DNA Extraction kit (Scientiﬁx) or from subject tissues (skeletal or cardiac muscle
and liver) by proteinase K digestion followed by salting-out. RNA was extracted
from cultured ﬁbroblasts using the Illustra RNAspinMini Kit (GE healthcare) and
cDNAwas generated using the SuperScript III First strand synthesis system (Invit-
rogen) as per manufacturers’ protocols. For analysis of nonsense-mediated decay
and mRNA splicing, ﬁbroblasts were cultured in medium with and without 
ng/µl CHX for  h before RNA preparation[].
PCR  S 
PCR products (primers supplied upon request) were either directly sequenced us-
ing GENEWIZ, ABI XL and BigDye v. Terminators (Applied Biosystems) as
per manufacturer’s protocols or sequenced after gel puriﬁcation using the MinE-
lute Gel Extraction kit (Qiagen).
A 
For patients P, P and P, the relevant exons containing both heterozygous
mutations in BCSL, MTHFDL and Corf respectively were PCR ampliﬁed
from genomic DNA and cloned into the TOPO®TA Cloning®system (Invitrogen)
as per manufacturer’s instructions before Sanger sequencing.
M 
Our molecular haplotyping protocol was adapted from a previous report[].
Brieﬂy, DNA was ampliﬁed from a single input molecule (- replicates) and

then the two target sites were genotyped via PCR-ampliﬁcation and Sanger se-
quencing. Genomic DNA (gDNA) was quantiﬁed using a TaqMan assay for Intra-
AluYb[] and pre-ampliﬁed using a primer-extension preampliﬁcation. In a 
well microtiter plate, gDNAwas diluted to .- genomes/well andmixed with X
PCR Buﬀer II (Applied Biosystems), .mMMgCl (Applied Biosystems), µM
each dNTP (Denville Scientiﬁc),  µMN oligonucleotide (Gene Link), .U Taq
polymerase (Amplitaq, Applied Biosystems). Reactions were cycled ( C × min,
then  cycles of  C ×  s,  C × min,     C ramp over  min,  C ×
 min). Products were diluted by adding µL of water. Each pair of target sites
was genotyped by PCR-ampliﬁcation and Sanger sequencing. Hemi-nested PCR
primerswere designedusingPrimer[] (http://primer.sourceforge.net/)
and ﬁltered by a custom Python script based on the following criteria: ) -bp
primer length, )   C primer Tm, ) two G/C bases at ’ primer end and one
G/C base at ’ primer end, ) -bp length for inner PCR amplicon, and )
minimum length for outer PCR amplicon. When necessary, criteria  and  were
relaxed to enable primer design. e ﬁrst round of PCR was multiplexed; µL of
preampliﬁed patient DNA was ampliﬁed in a  µL PCR reaction containing X
PCR Gold buﬀer (Applied Biosystems),  mM MgCl (Applied Biosystems), 
µM each dNTP (Denville Scientiﬁc), . µM of the forward-external and reverse
primer for each of the two sites and .U Amplitaq Gold DNA polymerase (Ap-
plied Biosystems). Reactions were cycled ( C ×  min, then  cycles of  C ×
 s,  C ×  s,  C ×  s). Products were diluted by adding µL of water.
Separate second round PCR reactions were run for each of the two amplicons; µL
of diluted ﬁrst round PCR product was ampliﬁed in a  µL PCR reactions con-
taining X PCR Gold buﬀer (Applied Biosystems),  mM MgCl (Applied Biosys-

tems),  µM each dNTP (Denville Scientiﬁc),  µM of the forward-internal and
reverse primers, .U Amplitaq Gold DNA polymerase (Applied Biosystems), .X
SyBr Green I (Invitrogen) and .X ROX (Invitrogen). Ampliﬁcation was assayed
bymelting curve analysis ( Fast Real Time PCR System, Applied Biosystems).
Successful reactionswere cleaned by adding UAntarctic phosphatase (NEB) and
UExonuclease I (NEB) and incubated for min at ; C. Enzymeswere deacti-
vated by incubating for  min at ; C. Cleaned samples were Sanger sequenced
(Genewiz or MGH DNA Sequencing Core). Sequence tracers were manually in-
spected, and a minimum of  informative reactions were required to determine
the phase.
SDS-PAGE   
Primary control and patient ﬁbroblasts were lyzed in RIPA buﬀer ( mMTris pH
.,  mMNaCl,  NP-, . sodium deoxycholate and . SDS) contain-
ing protease inhibitor cocktail (Roche)[]. Skeletal muscle samples and comple-
mentation assay sampleswere lyzed in SDS/glycerol solubilization buﬀer (mM
Tris pH.,  glycerol,  SDS, mM DTT, . Bromophenol blue), con-
taining protease inhibitor cocktail (Roche)[]. After sonication and heat denatu-
ration, - µg of whole lysate were run per lane on NuPAGE Bis-Tris gels (In-
vitrogen), and proteins were transferred to PVDFmembranes (Millipore). Protein
blots were later developed using ECL or ECL Plus detection reagents (Amersham
Bioscience).

A   
Antibodies includedMitoProﬁleTotalOXPHOSHumanWBAntibodyCocktail (MS
Mitosciences) at :, Porin ( Calbiochem) at :,, complex II -
kD subunit (A- Molecular Probes) at :,, complex II kDa subunit
(MSMitoSciences) at :, COXB (MSMitoSciences) at :, GFM
(--AP ProteinTech) at :, BCSL (--AP ProteinTech) at :,
CIA and ECSIT (kind gifts fromM Ryan andMMcKenzie, La Trobe University)
at :, UQCRFS (MS Mitosciences) at :, UQCRC (MS Mito-
sciences) at : and anti-mouse or rabbit HRP secondary antibodies (P,
P DakoCytomation).
D   PCR
e relative abundance of mtDNA vs nuclear DNA was tested in patient and con-
trol tissues as previously described previously []. e level of deleted mtDNA
in the skeletal muscle of patient P was determined by quantitative real-time
PCR as described[].
L- PCR  DNA
DNA extracted from the skeletal muscle of patient Pwas checked for large-scale
mtDNA rearrangements and the large mtDNA deletion mapped using long-range
PCR using primers F (nt -) and DR (nt -) which in control DNA
ampliﬁes a ,bp fragment. emtDNAwas then sequenced using an internal
primer closer to the break point (primer sequence available on request) as above.

S   L  
SNVs in candidate disease genes (TSFM, ACAD, ACADSB, Corf, LYRM and
MTCH) found in patients of Lebanese descent were assayed in genomic DNA
from  Lebanese probands ( ethnically matched control chromosomes) us-
ing SequenomMassARRAY iPLEX GOLD chemistry. Oligos were synthesized and
mass-spec QCed at Sigma Aldrich. All SNVs were genotyped in a multiplexed pool
of  assays, designed by AssayDesigner v.. software, starting with  ng of
DNA for each sample. Around  nl of reaction was loaded onto each position of a
-well SpectroCHIP preloaded with matrix. SpectroCHIPs were analyzed in au-
tomated mode by a SequenomMassArray Analyszer Compact mass spectrometer.
Variants were analyzed by Typer v.. software.
A. S  P
A.. ACAD  P
DNA from patient P, with lethal neonatal mitochondrial disease and complex
I deﬁciency, contained two mutations in ACAD, which were Sanger validated
(Fig. A.A) and determined to be compound heterozygous viamolecular haplotyp-
ing. Mutation c.G>C, p.AP was previously reported as pathogenic [].
Western blots show a reduction of complex I assembly factors CIA and ECSIT
protein levels, in keeping with previously published data[] (Fig. A.B) and dis-
tinct from a range of other complex I defects, which had normal levels of both as-
sembly factors. e secondmutation, c.T>A, p.IN, is located within a highly
conserved region (Fig. A.C) and the isoleucine residue is conserved within  of
 aligned vertebrate species based on the UCSC multiple genome alignments.

A.. POLG  P
DNA from patient P, with lethal neonatal mitochondrial encephalopathy and
clear complex I deﬁciency with lessmarked deﬁciency of complexes III and IV, con-
tained two mutations in POLG which were Sanger validated (Fig. A.) and deter-
mined to be compound heterozygous via molecular haplotyping. Both mutations
were previously reported as pathogenic[, ].
A.. BCSL  P
DNA from patient P, an infant girl with neonatal mitochondrial cytopathy and
complex III deﬁciency, contained twomutations in BCSL, which were Sanger val-
idated (Fig. A.A) and determined to be compound heterozygous by cloning ge-
nomicDNA.Mutation c.C>T (p.RX)waspreviously reported tobepathogenic[],
and this mutation was undetectable in cDNA without the presence of cyclohex-
imide, indicating that themRNA is degraded via nonsensemediateddecay (Fig. A.B).
e novel c.C>T (p.RC) mutation is located in a highly conserved region,
with identical residues in / aligned species (Fig. A.C) and alters the charge of
a highly conserved residue within the BCS_N superfamily domain (pfam).
Western blots show that although BCSL protein levels are within normal limits,
the patient shows a reduction of complex III protein UQCRFS, in keeping with
previous patient reports[] (Fig. A.D).
A.. COXB  P
DNA from patient P, a boy with neonatal onset of mitochondrial encephalopa-
thy,metabolic acidosis, and complex IV deﬁciency, contained a homozygousmuta-
tion in COXB, which was inherited from carrier parents (Fig. A.A). Protein blot

analysis showed a complete absence of COXB protein in both the patient’s mus-
cle andﬁbroblasts (Fig. A.B).ep.T residue is locatedwithin theCOXB:COXA
interface[] and is therefore likely to aﬀect complex IV assembly and stability.
A.. GFM  P  P
DNAfrompatients P andP, bothpresentingwithmitochondrial encephalopa-
thy, contained compound heterozygous mutations in GFM, which were Sanger
validated and phased by sequencing familial DNA and cDNA. P contained mu-
tations c.delT and c.C>T inherited from his mother and father, respec-
tively (Fig. A.A). P contained mutations c.delT and c.A>G, where the
mother carried only the former mutation and paternal DNA was unavailable for
testing (Fig. A.A). In both patients the c.delT allele was undetectable in cDNA
without CHX, indicating that the transcript undergoes nonsense mediated decay
(Fig. A.B). Protein blots showed reduced or absent levels of GFM protein in pa-
tientmuscle and ﬁbroblasts (Fig. A.C). In addition, protein blots showed reduced
amounts of OXPHOS proteins COX and NDUFB (Fig. A.C), indicating that the
GFMmissense mutations cause protein instability leading to a defect in mtDNA
translation and deﬁciency of complexes I, III and IV.
A.. TSFM   P  P
A previously reported pathogenic mutation (c.C>T, p.RW)[] in TSFM
was homozygous in DNA from patient P, with combined OXPHOS deﬁciency,
and patient P, with cardioencephalomyopathy. Sanger sequencing of familial
DNA showed segregation of the mutation with disease in both consanguineous
Lebanese families (Fig. A.A).Westernblots showed thatOXPHOSsubunitsCOX,

NDUFB and CIII core were deﬁcient in all patients and their aﬀected siblings
(Fig. A.B), consistent with a defect in a mitochondrial translation elongation fac-
tor such as TSFM.
A.. AARS  P
DNA from patient P, a stillborn fetus with mitochondrial myopathy and com-
bined complex I, III and IV was found to harbored one novel (c.G>A, p.RH)
and one previously reported pathogenic mutation (c.C>T, p.RW [] in
the mitochondrial translational protein AARS (Fig. A.A). e novel p.RH
mutation is located within a highly conserved region of the AARS protein and
the arginine residue is conserved in  out of the  aligned vertebrate species
(Fig. A.B). Western blots show that OXPHOS subunits COX, NDUFB and CIII
core  were deﬁcient in this patient’s skeletal muscle (Fig. A.C), consistent with
a defect in mtDNA protein synthesis.
A.. AGK   P  P
DNA from patients P and P, described in detail below, contained mutations
in the gene AGK. P had compound heterozygous mutations c.+T>C and
c.T>A inherited from her father and mother, respectively (Fig. A.A). P
contained ahomozygousmutation c.+G>T thatwas Sanger validated; parental
DNA was not available for testing (Fig. A.B). cDNA from patient P showed the
presence of a shorter isoform P (Fig. A.C), and subsequent sequencing identi-
ﬁed a bp deletion corresponding to the complete skipping of exon  consistent
with the observed splice mutation. Sequence analysis of the full length PCR prod-
uct in this patient validated the p.YX nonsense mutation. cDNA from patient

P showed that only a shorter isoform was present (Fig. A.C), and sequencing
conﬁrmed that it resulted from exon  skipping consistent with the observed
splicing mutation.
A. C I  AGK  NDUFB P
P presented to hospital with cardiac failure and hypertrophic obstructive car-
diomyopathy at  months of age. She had marked hyperlacticacidemia (-
mmol/l; normal range . – .) with metabolic acidosis. Clinical review revealed
generalized muscle weakness. She responded to medical management of cardiac
failure therapy and carnitine. Recurrent episodes of metabolic acidosis accompa-
nied viral infections. At age months she could pull to stand, sit without support
and crawl on all fours. Her speech, ﬁne motor and social skills were normal. She
walked in her third year. Bilateral cataracts were removed at / years of age.
ere were multiple episodes of congestive cardiac failure in childhood but the
cardiomyopathy was not progressive and cardiac failure medications were ceased
at age . She developed aphakic glaucoma. Fatigue was the major problem aﬀect-
ing her day to day life throughout childhood, with muscle power in adolescence
better than in childhood. She used a wheelchair for school from age  because
of fatigue and lactic acidosis on exertion. Her weight and height remained below
the  percentile with head circumference on the  centile. Commencement
of riboﬂavin therapy coincided with a degree of stabilization. At  years of age,
verbal intellectual functioning lay within the borderline range while performance
intellectual functioning was in the average range. Her school progress was within
normal limits for age with reading and spelling. Recurrent headaches were prob-
lematic in teenage years. At  years of age, verapamil was introduced because of

cardiac wall thickening. She developed osteopenia and premature ovarian failure.
Initial psychometric assessments were normal, but the gap between her abilities
and those of her peers widened. She graduated from high school, having required
a modiﬁed curriculum in the ﬁnal  years. At age  years  months, suddenly,
 weeks after contracting a viral illness, she developed worsening acidosis, had a
cardiac arrest and died. Skeletal muscle biopsy at the initial presentation revealed
punctuate red staining on Gomori trichrome preparations and markedly reduced
cytochrome oxidase staining. Electron microscopy revealed lipid vacuoles, with
subsarcolemmal accumulation of mitochondria in some ﬁbers. e mitochondria
were of abnormal shape, being rounded, with the usual internal pattern of cristae
replaced by amorphous granular interior.
Pwas the ﬁrst child of ﬁrst cousin parents of Pakistani origin. e pregnancy
was uncomplicated, but delivery was by lower segment cesarean section because
of unstable fetal lie. Birthweight was  gm, and Apgar scores were  and  at
 and  minutes, respectively. She developed respiratory distress and collapsed
within the ﬁrst hour of life with rapidly progressive circulatory failure, requiring
mechanical ventilation. At this time she had profoundmetabolic acidosis (pH .;
base excess -) and severe hyperlacticacidemia (up to  mmol/L). Urinary or-
ganic acids showed an elevated lactate. Liver function tests were normal. Car-
diac echo was suggestive of persistent pulmonary hypertension. Head ultrasound
showed no signiﬁcant abnormality, and EEG was not severely encephalopathic.
Bilateral cataracts were noted, and she had persistent thrombocytopenia. Hemo-
dynamic stability was restored but lactic acidemia persisted. Her parents were
counseled about the likely poor prognosis, and mechanical ventilation was with-
drawn at three days of age. She succumbedwithin one hour of extubation. Muscle

and liver samples were collected within two hour of death for histopathology and
respiratory chain enzymology, and a skin biopsy was performed to establish a cul-
tured ﬁbroblast line.
P had lethal infantile mitochondrial disease and her clinical presentation was
described previously due to her muscle biopsy being unusual in having nemaline
rods together with a severe complex I defect and borderline low complex III deﬁ-
ciency (Patient  in ref. []). She was born to unrelated parents (father is of
British decent andmother has Dutch ancestry) with no previous family history of
mitochondrial disease. Brieﬂy, she was born at  weeks gestation by caesarian
section because of failure to grow, and weighed g at birth. She required venti-
lation, was hypotonic, failed to thrive and developedworseningmetabolic acidosis
prior to her death at  months of age.
A. E C
Evolutionary conservation of protein AGK (Fig. .) was determined by identify-
ing RefSeq protein homologs in selected species via BLASTP[]. e following
GenBank sequences were then multiply aligned usingMUSCLE software[] with
default parameters: gi|, gi|, gi|, gi|, gi|,
gi|, gi|, gi|. Evolutionary conservation of BCSL
protein used the following GenBank sequences: gi|, gi|,
gi|, gi|, gi|, gi|, gi|, gi|,
gi|. Evolutionary conservation of ACAD protein used the following
GenBank sequences: gi|, gi|, gi|, gi|,
gi|, gi|, gi|, gi|. Evolutionary con-
servation ofAARSprotein used the followingGenBank sequences: gi|,

Figure A.1: Variant prevalence in cases and controls. Number of variants present
in cases (red) compared to control individuals of European ancestry (gray). Barcharts
display the mean number of variants present per sample, within autosomal coding re-
gions of 1034 mitochondrial genes that were well-covered in all individuals. Variants
are categorized by rare (<0.005 allele frequency), protein-modifying (PM), heterozy-
gous, and recessive-type (homozygous or 2 heterozygous variants present in the same
gene) ﬁlters. Error bars indicate standard error of mean.
gi|, gi|, gi|, gi|, gi|, gi|,
gi|, gi|. Evolutionary conservationofNDUFBprotein (Fig. A.C)
used the following GenBank sequences: gi|, gi|, gi|,
gi|, gi|, gi|, gi|, gi|, gi|,
gi|, gi|, gi|, gi|

Figure A.2: ACAD9 variants in patient P1. (A) Electropherograms show Sanger
sequence validation of the two mutations. (B) SDS-PAGE western blotting of ﬁbrob-
lasts from control (C), patient P1, and patient controls with mutations in NDUFS6
(FS6), NDUFS4 (FS4), C20orf7 (C20) and C8orf38 (C8) Asterisk indicates non-
speciﬁc band in ECSIT blot. (C) Multiple sequence alignment of ACAD9 protein
region surrounding the novel p.I87N mutation (asterisk).

Figure A.3: POLG mutations in P2. Electropherograms show Sanger sequence
validation of the two mutations found in POLG.
Figure A.4: BCS1L mutations in P11. (A) Electropherograms show Sanger se-
quence validation of the two mutations. (B) Sanger sequencing of cDNA with (+)
and without (-) cycloheximide (CHX). (C) Multiple sequence alignment of BCS1L
protein region surrounding the novel p.R90C mutation (asterisk). (D) SDS-PAGE
western blots of patient and control (C1 and C2) skeletal muscle.

Figure A.5: COX6B1 mutations in P17. (A) Family pedigree of P17. Carrier sta-
tus of the parents was conﬁrmed by Sanger sequencing parental DNA (WT represents
Wild-Type allele). (B) SDS-PAGE western blots of OXPHOS complex subunits in
patient and control (C1, C2) ﬁbroblasts (Fib) and skeletal muscle (Skm). Loading
controls included CV  (for top panel) and Porin (for COX6B1 panel).

Figure A.6: GFM1 mutations in P18 and P29. (A) Family pedigrees of P18 and
P29, showing the mutant alleles segregated with disease in the families. For P29 the
c.720delT was inherited from her mother, DNA from her father was unavailable for
testing but is a presumed carrier of the c.910A>G (WT represents Wild-Type allele)
or that this mutation is de novo. textbf(B) Chromatograms from Sanger sequencing
of cDNA +/- cycloheximide (CHX). (C) SDS-PAGE western blots of GFM1 and OX-
PHOS complex subunits in patient and control (C1, C2) ﬁbroblasts (Fib) and skeletal
muscle (Skm). Loading controls included CII 70kD (for top panel) and CII 30kD (for
GFM1 panel).

Figure A.7: TSFM mutations in P27 and P28. (A) Family pedigrees of P27
and P28. Sanger sequencing of familial DNA conﬁrmed segregation of mutant alle-
les with disease in both consanguineous Lebanese families. P27 and his aﬀected sib-
ling (P27S) were homozygous for c.997C>T. Their parents and 2 unaﬀected siblings
were carriers (WT represents Wild-Type allele), whereas the 3rd unaﬀected sibling
was homozygous wild-type. P28 and her aﬀected sibling (P28S) were homozygous
for c.997C>T while their unaﬀected sibling was a carrier. DNA from both unaﬀected
parents was unavailable for testing however are presumed to be carriers. (B) SDS-
PAGE western blot of OXPHOS complex subunits in patients (P27, P28), aﬀected
patient siblings (P27S, P28S) and control (C). CV  was used as a loading control.

Figure A.8: AARS2 mutations in P40. (A) Electropherograms show Sanger se-
quence validation of the two mutations. (B) Multiple sequence alignment of AARS2
protein region surrounding the novel p.R329H mutation (asterisk). Grey indicates
conserved amino acids. (C) SDS-PAGE western blots of OXPHOS complex subunits
in patient and control skeletal muscle. CV  was used as a loading control.

Figure A.9: AGK mutations in P41 and P42. (A) Family pedigree for P41.
Sanger sequencing of familial DNA conﬁrmed segregation of mutation allele with
disease. P41 is compound heterozygous for the c.297+2T>C and c.1170T>A. Her
parents are carriers and her unaﬀected sibling was not tested (WT represents Wild-
Type allele). (B) Family pedigree for P42. Sanger sequencing of P42 conﬁrmed her
homozygous state for the c.1131+1G>T mutation, her unaﬀected consanguineous
parents were presumed to be carriers as DNA was unavailable for testing. (C) PCR
products of AGK exon 1-16 from control and patient’s ﬁbroblast cDNA -/+ cyclo-
heximide (CHX). A full length PCR product of 1417bp was detected in control (-/+
CHX). Sequence analyses of smaller products are summarized in the schematic repre-
sentation of the AGK genomic structure indicating the location and consequences of
the mutations identiﬁed.

Figure A.10: NDUFB3 mutation in P3. (A) Family pedigree of patient P3.
Sanger sequencing of genomic DNA conﬁrmed homozygosity in P3 for the c.64C>T
(p.W22R) mutation and carrier status of the mother (WT represents Wild-Type al-
lele), Paternal DNA was unavailable for testing but is presumed to be a carrier. (B)
Microarray-based detection of copy number change for the Chromosome 2 area sur-
rounding the NDUFB3 locus (chromosome 2q33.1) using the high-resolution Illumina
HumanCytoSNP-12 array (version 2.1), Blue dots indicate B-allele frequency (BAF)
data for all SNPs in region and smoothed LogR data (solid red line centred at 0) are
shown for P3. The LogR data indicate that there are no detectable deletions around
the NDUFB3 locus. The 1.3Mb region of Long Contiguous Stretch of Homozygos-
ity (LCSH) is also shown (solid grey bar). (C) ClustalW alignment of NDUFB3 or-
thologs shows conservation of the p.W22 residue (asterisk) as well as the adjacent
lysine residue, which undergoes N6-acetylation (triangle).

Figure A.11: Estimated MitoExome diagnostic eﬃcacy in a retrospective co-
hort. (A) Retrospective cohort containing 291 patients with biochemically proven
OXPHOS disease, of which 124 cases (blue) had pre-existing molecular diagnoses
obtained via traditional sequencing. 38 of the remaining 167 cases resistant to tradi-
tional methods were sampled for MitoExome sequencing (red and light gray). (B)
Estimated eﬃcacy of MitoExome sequencing in the 124 cases with a pre-existing
molecular diagnosis. (C) Estimated MitoExome diagnostic eﬃcacy in cohort of 291
cases, where rates of molecular diagnosis for the 38 sequenced patients were extrapo-
lated to the remaining 129 patients lacking a diagnosis. (D-F) Estimated MitoExome
sequencing detection and bioinformatic prioritization of 98 unique variants (D), the
198 unique causal variants (where homozygous variants each count as two causal alle-
les) (E), and 124 patient cases (F). Asterisk indicates estimated detection of variants
based on sequence coverage observed in 38 sequenced individuals, and prioritization
using the MitoExome annotation pipeline.

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B.. P  (P)
P was investigated at  years of age with an acquired strabismus (bilateral in-
ferior oblique overaction thought to be due to an internuclear ophthalmoplegia)
and mild impairment of visual acuity. A normal ophthalmological examination
had been documented one year previously. ere was a past history of develop-
mental delay aﬀecting linguistic and to a lesser extent coordination abilities. She

had mild diﬃculty performing tandem walking and standing on one leg and was
unable to ride a bicycle. Her printing was legible but slow and immature for her
age. She scored months below her age level on the Schonell GradedWord Read-
ing Test. e optic fundi showed slightly pale optic discs. Visual acuity was /
on the right and / on the left. CT scan revealed diminished attenuation within
the putamina, the left caudate and the subcortical white matter of the parietal
and occipital regions. MRI showed nearly symmetrical high signal on T lesions
involving the lentiform nuclei, caudate nuclei, mid-brain tectum, red nuclei, cor-
pus callosum and subcortical white matter.
Urine organic acid and amino acid levels were normal. ree separate fast-
ing CSF samples showed elevated lactate (., . and . mmol/L, reference
range .-.) and mildly elevated pyruvate (,  and  µmol/L, refer-
ence range -). Blood lactate and pyruvate were consistently normal.
Cardiovascular, respiratory and abdominal systemswere normal on physical ex-
amination. Histology, histochemistry and electronmicroscopy of muscle biopsy
material were normal. Electrocardiography showed a short PR interval and delta
waves consistent withWolﬀ-Parkinson-White syndrome. Shewas prescribedmul-
tivitamins including Riboﬂavin, iamine and Ubidecanone. Subsequently she
stopped experiencing night terrors which were previously occurring almost ev-
ery night and no deterioration of her condition has been noted. An intellectual
assessment at  years of age showed verbal, performance and full scale abilities
below the . percentile level. At  years of age she is working in her family’s
shop where she can stack the shelves, serve customers and handle money. Cranial
MRI shows no change in the lesions.
P’s maternal ﬁrst cousin also had Leigh-like changes on brain MRI. At  years

of age he was more severely aﬀected with global developmental delay, optic at-
rophy, mild bilateral pyramidal tract signs and coordination diﬃculty. He had
signiﬁcantly impaired visual acuity, to / in the right eye and / in the left.
He was mildly obese, had small hands and feet, a left single palmar crease, mildly
dysmorphic facies and a past history of bilateral inguinal hernia repair. Plasma
lactate level was normal but CSF lactate was elevated at .mmol/L, with a raised
lactate/pyruvate ratio of . He also showed evidence of Wolﬀ-Parkinson-White
syndrome on electrocardiography. He was commenced on similar high dose mul-
tivitamin therapy. At  years of age there was an acute deterioration with right
sided weakness and ataxia. MRI showed progression of T signal abnormality af-
fecting periaqueductal grey matter of the midbrain and upper pons. With rehabil-
itation he recovered much of the lost function.
B.. P  (P)
P was the ﬁrst born child of non-consanguineous Australian parents and had no
signiﬁcant neonatal problems. Early milestones were age appropriate and there
was no overt history of neurodevelopmental regression. She was initially inves-
tigated at  years of age for excess weight gain and hypertension associated with
elevated cortisol and ACTH suggestive of Cushing’s disease. Her height was on the
 centile and weight on the  centile.
Cerebral MRI identiﬁed a mm pituitary adenoma and bilateral symmetrical
abnormal high signal areas in the putamen, globus pallidus and brainstem. MRI
performed onemonth later showedmarked progression of previous basal ganglia,
midbrain and medullary disease with new extensive bilateral frontoparietal and
occipital white matter changes. Following the general anaesthetic for theMRI, P

experienced a right focal seizure that progressed to a tonic clonic seizure. High
CSF and serum lactate levels were noted (serum: .mmol/L, CSF: .mmol/L).
She experienced a second seizure one week later which resulted in respiratory ar-
rest and she was unable to be weaned from mechanical ventilation. She had fur-
ther neurological deterioration. Care was withdrawn and she soon succumbed,
ﬁve weeks after her initial admission.
Tissue biopsies and cell lines from all  patients had deﬁcient activities of OX-
PHOS complexes I and IV, with deﬁcient complex III in some samples (Fig. B.A).
ese combinedOXPHOS defects were not due tomtDNA depletion sincemtDNA
levels estimated by qPCR [] were normal to elevated in all tissues studied, at
 to  of normal mean in muscle biopsies from the  patients and  of
normal mean in P liver biopsy.
B. N    
Roughly  of our sequence aligned to the target region resulting in an average
of x coverage of nuclear DNA-encoded exons and >x coverage of mtDNA.
For accurate variant detection, we required that each target base have independent
sequence data fromat least  reads. Based on this cutoﬀ, ~of theMitoExome
was well covered. Regions of poor coverage tended to be GC-rich, consistent with
previous reports [].

B. S M
B.. Q RT-PCR (RT-PCR)
RNA was extracted from cultured patient ﬁbroblasts using the Illustra RNAspin
Mini Kit (GE Healthcare) and cDNA was generated using the TaqMan Reverse
TranscriptionKit (AppliedBiosystems) according tomanufacturers’ protocols. For
ND qRT-PCR, residual genomic DNA was digested using the Turbo DNA-free Kit
(Ambion). Quantitative evaluation of ND, MTFMT, PDF, MAPD and HPRT ex-
pression was performed using the Taqman Human HPRT Endogenous Control
Gene Expression Assay (Applied Biosystems), the TaqMan HumanMTFMT Gene
Expression Assay, Hs__m (Applied Biosystems), the TaqMan Human
PDFGene expressionAssay (Hs_m), theTaqManHumanMAPDGene
expression Assay (Hs_m) orND probes and primers described previ-
ously []. Cycling was performed in a BioRad iQ iCycler and results were an-
alyzed with BioRad iQ Optical System Software v.. Dilution series were gen-
erated to calculate probe eﬃciency and to validate analysis via the ΔΔCt or the
Pfaﬄmethod [, ]. ree independent qPCR experiments were performed,
each in triplicate.
B.. F N- M S 
C IV P D
Complex IV was immunoprecipitated from control and patient ﬁbroblasts using
MitoSciences’ Complex IV Immunocatpure kit (MS-) followingmanufacturer’s
instructions. .mg of puriﬁedmitochondria were solubilized with n-dodecyl--
D-maltoside (Sigma-Aldrich), pulled downwith .uL ofmatrix in a total volume

of .mL. Bound Complex IV was eluted with uL of  SDS solution.
S P
Complex IV was prepared as described above and dissolved in X LDS sample
buﬀer (Invitrogen) with  mM dithiothreitol (Pierce) for  min at  C, fol-
lowed by  min at RT. Proteins were then alkylated with iodoaceteamide (Sigma)
added to a ﬁnal concentration of mMfor min at RT in the dark. e complex
was separated by gel electrophoresis on a NuPAGE - Bis-Tris gel according to
themanufacturer’s instructions (Invitrogen). A band corresponding to theMWof
COI was excised and subjected to in-gel Lys-C digestion over night at  C [].
Peptides were extracted twice from the gel with  acetonitrile,  formic acid.
e peptides were vacuum concentrated to dryness and resuspended in  ace-
tonitrile,  formic acid for mass spectrometry analysis.
LC-MS/MS A
epeptides were separated using a homemade column packed with µmReprosil
C resin (Dr. Maisch GmbH) and fashioned with a PicoFrit nanoelectrospray
emitter (New Objective). e column was connected to a -Series nano-LC
pump (Agilent) and coupled to a LTQ-Velos-Orbitrap mass spectrometer (er-
moFisher). e following buﬀers were used for separation: Buﬀer A: . formic
acid and Buﬀer B: . formic acid/ acetonitrile. A -minute separation was
performed: - min at  B and . µl/min, - min at -. B and .
µl/min, - min at .- B and . µl/min, - min at - B and .
µl/min, -min at B and. µl/min, -min at B and. µl/min. e
peptides (~ of digest) were ionized with a spray voltage of .kV. Each duty

cycle in the min data acquisitionmethod included anOrbitrap survey scan -
 m/z range and , resolution, and LTQ-based data-dependent MS/MS
of top most abundant precursors in the survey followed by static events MS/MS
form/zs ., ., . corresponding to the z= states of the unformylated,
formylated and des-Met species of the N-terminal peptide of COI (MFADRWLF-
STNHK). Dynamic exclusion was enabled for data dependent scans with the fol-
lowing parameters: repeat count was set equal to , precursor m/z tolerance was
+/-.ppm and the exclusion duration was set at  seconds.
D A
Extracted ion chromatographs (XICs) were generated from the Orbitrap survey
scans based on the z= states of the unformylated, formylated anddes-Met species
of the N-terminal peptide of COI (m/zs ., ., ., .
ppm, respectively) using XCalibur software (ermoFisher Scientiﬁc). e identi-
ties of the peaks corresponding to these species were veriﬁed using the accompa-
nying staticMS/MS spectra (Fig. S). e areas under these peaks were integrated
using the Genesis peak detection algorithm included in XCalibur with all standard
defaults. Peak areas were further normalized to the peak area of a distal peptide of
COI (VFSWLATLHGSNMK, m/z ., z=) to ensure that subsequent com-
parisons among samples were based on an equivalent amount of COI.

Figure B.1: mtDNA transcript analysis. The level of ND1 relative to HPRT ex-
pression was analyzed by qRT-PCR. There is no reduction in ND1 transcription which
could have accounted for the lack of ND1 translation. Error bars show ± 1 s.e.m of 3
qRT-PCR experiments, each performed in triplicate.

Figure B.2: Additional support for mutation pathogenicity. (A) MUSCLE align-
ment of the protein sequence from MTFMT orthologues shows strong conservation
of p.S125 and p.R128 and moderate conservation of p.S209. Note that p.S209 lies
within a solvent exposed region of a leucine zipper and is substituted solely by small
polar residues. (B) MUSCLE alignment of the mRNA sequence from MTFMT or-
thologues shows conservation of c.626C. (C) Location of patient variants homolo-
gous to S125, R128 and S209 in the crystal structure of E. coli FMT are shown in
purple[232]. Red indicates sequence that is deleted or frameshifted. (D) MTFMT
expression relative to HPRT expression was analysed in patient ﬁbroblasts using a
probe across the exon 4/5 junction. P1 has only 9% of control expression in the ab-
sence of CHX and P2 has 56%, consistent with essentially complete exon skipping
of the c.626C>T containing allele. Error bars represent ±1 s.e.m of 3 independent
qRT-PCR experiments, each performed in triplicate.

Figure B.3: Analysis of PDF and MAP1D Expression, Related to Fig. 3.5.
The level of PDF and MAP1D relative to HPRT expression was analyzed by qRT-
PCR. There is no increase in steady state levels of PDF or MAP1D transcripts, sug-
gesting the increased proportion of the deformylated N-terminal peptide of COX1 in
patient ﬁbroblasts is not due to increased PDF levels. Error bars represent ±1 s.e.m
of 3 independent qRT-PCR experiments, each performed in triplicate.

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